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ABSTRACT

Age-related macular degeneration (AMD) is a leading cause of irreversible
blindness among adults, age 60 and older, in developed countries. While oxidative stress
is implicated in the pathogenesis of AMD, clinical studies have shown that dietary
antioxidants can delay progression of AMD. Currently, there is no FDA-approved
treatment for AMD. Therefore, we hypothesized that N-acetylcysteine amide (NACA), a
thiol antioxidant, would protect retinal pigment epithelium and impede the progression of
retinal degeneration. The goal of this work was to evaluate the efficacy of NACA in
preventing retinal pigment epithelial cell and photoreceptor death in AMD models. To
achieve this, we used the oxidants tert-butyl hydroperoxide (TBHP) and sodium iodate
(NaIO3) in a cell model and an animal model to evaluate the effects of NACA. Our data
suggest that pretreatment with NACA reduces the sub-lethal (but not lethal) effects of
TBHP in primary cultures of human retinal pigment epithelial cells. NACA significantly
improves cell survival when administered prior to and during the occurrence of oxidative
damage similar to that observed in the development of dry AMD. In the chemicallyinduced retinal degeneration animal model, NACA eye drops partially prevented
reduction in visual function, as determined from electroretinograms (ERG) recorded 36
hours after NaIO3 injection. Other toxic effects were observed at a later time point after
NaIO3 injection: increased lipid peroxidation (as measured by formation of 4hydroxynonenal, 4-HNE), elevated cysteine levels, and death of photoreceptors resulting
in outer nuclear layer thinning. NACA eye drops reversed these toxic effects. In
conclusion, this potent antioxidant should continue to be investigated as a treatment for
AMD.
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SECTION

1. INTRODUCTION

1.1. OXIDATIVE STRESS
Oxidative stress results from an imbalance between reactive species and
antioxidant defense processes, that lead to a highly oxidizing environment that is harmful
to cells [1]. The term “reactive species” includes both free radicals that contain one or
more unpaired electrons, and non-radicals with strong oxidizing potential. It encompasses
reactive oxygen, nitrogen, halogen, and sulfur species. Figure 1.1 shows the major
reactive species relevant to physiological processes [2]. This section will focus on the
definition of reactive oxygen species (ROS), sources of ROS, redox balance, and
oxidative stress and its by-products.

Figure 1.1 Reactive oxygen species and reactive nitrogen species (adapted from slide
player [2]).
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1.1.1. The Definition of ROS. Reactive species, including ROS, play an
important role in a cell’s life and death [3-5]. The National Cancer Institute defines ROS as
“a type of unstable molecule that contains oxygen and easily reacts with other molecules
in a cell.” These molecules can damage lipids, nucleic acids, and proteins, which can
result in cell death. The terms “ROS,” “oxygen-derived species,” and “pro-oxidant
species” are generally interchangeable in biological scientific literature [6]. ROS can be
classified as radicals or non-radicals. Radicals are chemical species with an unpaired
electron, such as superoxide (O2•-), hydroxyl radical (HO•) and peroxyl radicals (formed
from non-radical lipid peroxides and peroxides of proteins and nucleic acids). Hydrogen
peroxide (H2O2) is a non-radical, but it forms the most reactive free radical, hydroxyl
radical (HO•), through the Fenton reaction. Figure 1.2 shows the Lewis structures of
molecular oxygen, superoxide, hydrogen peroxide, and hydroxyl radical [7]. Their energyand electron-transfer reactions are shown in Figure 1.3 [8].

Figure 1.2 The Lewis structures for molecular oxygen and its singlet electron derivatives
superoxide, hydrogen peroxide, and hydroxyl radical (adapted from Mailloux, R.J. [7]).

1.1.2. Sources of ROS. ROS can be generated endogenously or exogenously [6,
9]

. Endogenous sources of ROS include leakage of electrons to O2 in the mitochondrial
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respiratory chain (Figure 1.4) [10], direct or indirect generation by numerous enzymes, and
the Fenton reaction (Figure 1.5) [11]. In addition, certain diseased states may increase
endogenous ROS production as a result of dysfunctional regulation of the immune
response. High-energy electromagnetic radiation (UV, X-ray, and γ radiation), certain
foods, medicines (acetaminophen, doxorubicin, and nitrofurantoin), and illicit drugs
(methamphetamine and heroin), cigarette smoke, pollutants, and xenobiotics are common
exogenous sources of ROS [12-16].

Figure 1.3 Formation of ROS through energy- and electron-transfer reactions (adapted
from Katerina K. & Cosa G. [8]).

1.1.3. Redox Balance and Oxidative Stress. ROS can play either beneficial or
deleterious roles in the body. Certain ROS and their derivatives are involved in important
physiological functions, such as regulation of vascular tone, control of erythropoietin
production, and hypoxia-inducible functions, smooth muscle relaxation, signal
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transduction, and maintenance of redox homeostasis [3]. However, mitochondria-derived
ROS can serve as a meditator of cell death in eukaryotes [17]. ROS scavengers (also
known as antioxidants) can remove extra ROS and stabilize the redox balance in cells.
Figure 1.6 shows the mechanism of redox homeostasis [3]. With an overwhelming
production of ROS, the redox balance can be shifted toward a more oxidative status, in
which the overproduction of ROS is associated with numerous disorders, such as
Alzheimer’s disease, cardiovascular disease, atherosclerosis, cataract, and retinal
degeneration [4, 9, 18]. A summary of oxidative stress-induced diseases in humans is shown
in Figure 1.7 [4]. More details about oxidative stress by-products and the role of oxidative
damage will be discussed in the following sections.

Figure 1.4 The ROS generation in the mitochondria (adapted from Sabharwal, S. and
Schumacker, P. [10]).
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Figure 1.5 Sources and generation of different reactive oxygen species (adapted from
Ajuwon, O.R. et al. [11]).

Figure 1.6 Mechanisms of redox homeostasis: balance between ROS production and
various types of scavengers (adapted from Dröge, W. [3]).
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Figure 1.7 Oxidative stress-induced diseases in humans (adapted from Pham-Huy, L.A. et
al. [4]).

1.1.4. Oxidative Damage By-Products and Their Formation. An excess of
ROS, especially hydroxyl (HO•) and peroxyl (ROO•) radicals, hydrogen peroxide (H2O2),
and superoxide radical anion (O2•ˉ), is associated with oxidation-induced damage to
DNA, proteins, and fatty acids. In this section, the formation of DNA oxidation byproducts, protein carbonyls, and lipid peroxidation by-products will be discussed.
Lipid peroxidation is a free radical chain reaction in which free radicals attack the
carbon-carbon double bonds of polyunsaturated fatty acids (PUFAs), generating lipid
hydroperoxides and electrophilic α,β-unsaturated carbonyl derivatives of these lipids [19].
Lipid peroxidation consists of three steps: initiation, propagation, and termination (see
Figure 1.8) [12, 20]. In the initiation step, a free radical (R•) attacks the methylene bridge (CH2-) of an unsaturated fatty acid and abstracts hydrogen to produce a lipid radical (a
carbon radical). A stable conjugated diene is formed after molecules are rearranged
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(Figure 1.8, step 1). In the propagation step, the lipid radical (carbon radical) reacts with
O2 to form a new peroxyl radical (ROO•) (Figure 1.8, step 2), which abstracts H• from an
adjacent lipid, forming a lipid hydroperoxide (ROOH) plus a new lipid radical (Figure
1.8, step 3) that will then continue the chain reaction. In the termination step, an
antioxidant donates hydrogen to the lipid peroxyl radical (ROO•), resulting in a nonradical product (Figure 1.8, step 4). Aldehydes, such as malondialdehyde (MDA) and 4hydroxynonenal (4-HNE), (Figure 1.9, [21]) may also be formed during lipid peroxidation.
MDA is mainly formed from the peroxidation of PUFAs with more than two double
bonds, such as linolenic acid, arachidonic, and docosahexaenoic acid, whereas 4-HNE is
formed during peroxidation of ω-6 (omega-6) PUFAs, such as linolenic acid and
arachidonic acid [22]. These by-products are associated with human tissue injury and
disease [23].
DNA’s localization in the nucleus affords it some protection from ROS, and it is
relatively stable under physiological conditions. DNA is not very susceptible to direct
oxidative damage from weak ROS, such as O2˙- , NO˙, and H2O2 [24]. However, when
DNA (or RNA) is exposed to highly reactive OH˙, adducts may be generated. For
example, OH˙ can attack guanine at C-8 to form 8-hydroxyguanine (8-OH-dG) [6]. Figure
1.10 shows the modification of DNA bases by HO˙ radicals [25]. In addition, electrophilic
lipid peroxidation by-products (such as MDA and 4-HNE) can cause DNA damage.
MDA can react with DNA at a physiological pH to form the adducts deoxyguanosine,
deoxyadenosine, and deoxycytidine [26]. 4-HNE is the most genotoxic, while MDA is the
most mutagenic, but both of them may contribute to human disease [27].
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Figure 1.8 The four steps of lipid peroxidation (adapted from Ayala, A. et al [12]).

Figure 1.9 Chemical structures of 4-hydroxynonenal (4-hydroxy-trans-2-nonenal, 4HNE) and malondialdehyde (MDA) (modified from Pizzimenti, S. et al. [21]).

There is a high abundance of protein in biological systems; therefore, proteins are
often a target for oxidative damage. Proteins can be attacked by ROS directly or
indirectly by lipid peroxidation by-products, and the resulting damaged proteins can
affect enzyme activity or alter cellular functions [6]. Protein carbonyls are the most well-
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known biomarkers for protein peroxidation and are associated with many human
diseases, including diabetes, Alzheimer’s disease, and chronic lung disease [28]. Table 1.1
lists the oxidants involved in protein oxidation and their major sites of reaction [29]. Direct
protein carbonylation often happens on the side chains of proline, arginine, lysine and
threonine residues. Figure 1.11 shows the structures of carbonyl derivative products of
amino acid side chains: 2-pyrrolidone from prolyl residues, glutamic semialdehyde from
arginyl and prolyl residues, α-aminoadipic semialdehyde from lysyl residues, and 2amino-3-ketobutyric acid from threonyl residues [30].

Figure 1.10 Reactions of hydroxyl radical with DNA bases and their major products
(adapted from Dissanayake, N. et al. [25]).
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Table 1.1 The summary of protein modifications induced by reactive oxidants
Oxidant

Major sites of reaction

HO•
RO•
ROO•
NO2•
O2•ˉ

All residues
Most residues
Cys, Met, Trp, Tyr
Cys, Tyr/Trp radicals
Superoxide dismutase, some transition metal ions, Fe-S
clusters, Tyr/Trp radicals
1
O2
Cys, Met, Trp, Tyr, His
HOCl/HOBr
Cys, Met, cysteine, His, Lys, Trp, α-amino group
Peroxynitrous acid (ONOOH)
Cys, Met, Tyr, Trp
Reactive aldehydes
Cys, Arg, Lys, His, α-amino group
UVB light
Trp, Tyr, cystine
H2O2
Cys, selenocysteine
Cys, Cysteine; Met, Methionine; Trp, Tryptophan; Tyr, Tyrosine; His, Histidine; Lys,
Lysine; Arg, Arginine. (Table was modified from Davies, M. [29]).

Figure 1.11 The structures of carbonyl derivatives produced by direct oxidation of amino
acid side chains (adapted from Dalle-Donne, I. et al. [30]).

1.2. ANTIOXIDANTS
The primary role of antioxidants is to neutralize excess ROS, thereby protecting
the cell from their deleterious effects. Antioxidants can be classified as enzymatic or nonenzymatic [4]. Superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase, and
thioredoxin are examples of enzymatic antioxidants (Table 1.2) [31, 32]. The non-enzymatic
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antioxidants can be further divided into metabolic antioxidants and nutrient antioxidants
(Table 1.3) [31]. Glutathione (GSH), melatonin, and α-lipoic acid are metabolic
antioxidants. Vitamin E, vitamin C, carotenoids, omega-3 and omega-6 fatty acids, trace
metals (selenium, manganese, and zinc), and flavonoids are nutrient antioxidants.
Oxidative stress occurs when oxidants and antioxidants are not balanced in a cell, leaving
excess oxidants to damage cellular components.

Table 1.2 Enzymatic Antioxidant Defenses
Enzymatic Antioxidants

Catalyzed Reaction

Superoxide dismutase (SOD)

O2•ˉ + O2•ˉ +2H+ → H2O2 + O2
Enzyme-Cu2+ + O2•ˉ → Enzyme-Cu+ + O2
Enzyme-Cu+ + O2•ˉ + 2H+ → Enzyme-Cu+ + H2O2
Mn(Ш) + O2•ˉ ⇆ [ Mn(Ш) - O2•ˉ ] → Mn2+ + O2
Mn2+ + O2•ˉ ⇆ [ Mn2+ - O2•ˉ ]+ 2H+→ Mn(Ш) + H2O2
2H2O2 → O2 + 2H2O
Catalase-Fe(Ш) + H2O2 → Compound І + H2O
Compound І + H2O2 → Catalase-Fe(Ш) + H2O + O2
2GSH + H2O2 → GSSG + 2H2O
2GSH + ROOH → GSSG + H2O + ROH
TRX-(SH)2 + Protein-S2 ⇆ TRX-S2 + Protein-(SH)2
2 R’-SH + ROOH ⇆ R’-S-S-R + H2O + ROH
RX + GSH → R-S-GSH + HX

Catalase (CAT)

Glutathione peroxidase
(GPx)
Thioredoxin (TRX)
Peroxiredoxin (PRX)
Glutathione transferase (GST)

RX: halogenated hydrocarbons [33]. Table was modified from Birben, E. et al. [31].

Table 1.3 Non-Enzymatic Antioxidant Defenses
Metabolic antioxidant
Glutathione
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Table 1.3 Non-Enzymatic Antioxidant Defenses (Cont’d)
Nutrient Antioxidant
Vitamin A

All trans retinol

Vitamin C

Ascorbic acid

Vitamin E

α-Tocopherol
Ref [34]

β-Carotene

(Table was modified from Birben, E. et al. [31]).
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1.2.1. Glutathione. Glutathione (γ-glutamylcysteinylglycine, GSH) is a watersoluble endogenous tripeptide (structure in Figure 1.12) with γ-carboxyl groups that make
this small peptide relatively more stable as compared to other peptides. GSH, the most
abundant thiol present in mammalian cells, has concentrations of up to 10 mM [35].

Figure 1.12 The structure of glutathione.

GSH cannot penetrate cell membranes; therefore, intracellular GSH must be
synthesized through both de novo and salvage pathways (Figure 1.13, modified from [36,
37]

). The first and rate-limiting step of de novo synthesis requires ATP and γ-

glutamylcysteine ligase (also known as γ-glutamylcysteine synthetase (GCS) [38]. Then,
the dipeptide is combined with glycine by glutathione synthetase. The salvage synthesis
pathways of GSH proceed via three different routes: reduction from GSSG, formation
from the products of GSH hydrolysis, or production from amino acids and dipeptides
transported into the cell by γ-glutamyl transpeptidase (Figure 1.13). GSH can be broken
down by γ-glutamyltransferase (GGT), which cleaves to the gamma linkage and
generates cysteinylglycine.
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Figure 1.13 Glutathione synthesis and enzymes involved in GSH metabolite.
GCL: γ-glutamylcysteine ligase, GS: Glutathione synthetase, GGT: γglutamyltransferase (or γ-glutamyltranspeptidase), G6P: glucose-6-phosphate, G6PD:
glucose-6-phosphate dehydrogenase, 6PG: 6-phosphogluconate, NADPH: nicotinamide
adenine dinucleotide phosphate, GR: GSH reductase, GPx: GSH peroxidase.

The functions of GSH include antioxidant defense against reactive oxygen species
(ROS) and electrophiles to maintain the cellular reducing environment, cysteine
reservation, nitric oxide transportation, xenobiotic detoxification, and involvement in
redox signaling-related transcription factor operations

[36, 39]

. In the xenobiotic

detoxification pathway, GSH can directly interact with excess ROS or conjugate with
electrophile metabolites, which are then exported from the cell. Figure 1.14 shows the
role of GSH in detoxification of xenobiotics and ROS balance, processes that may lead
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to pathological conditions if dysregulated [36]. The effects of an imbalance between
ROS and antioxidant defenses depend on the level of ROS production, as shown in
Figure 1.15 [8].

Figure 1.14 Relationship between GSH homeostasis and pathologies (adapted from
Lushchak, V.I. [36])

1.2.2. Glutathione Reductase. GSH can be oxidized to glutathione disulfide
(GSSG) by glutathione peroxidase (GPx).The function of the enzyme glutathione
reductase (GR) is to reduce GSSG to GSH using NADPH generated by glucose-6phosphate dehydrogenase (G6PD) in the pentose phosphate pathway [38] (Figure 1.13).
Patients with age-related macular degeneration (AMD) show both lower glutathione
reductase activity and glutathione peroxidase activity in the blood, as compared to
controls [40, 41].
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Figure 1.15 Sources of ROS, antioxidant defenses, and subsequent biological effects
depending on the level of ROS production (adapted from Krumova, K. & Cosa, G. [8]).

1.2.3. Glutathione Prodrugs and N-Acetylcysteine Amide (NACA). Direct
administration of GSH as a therapeutic agent is ineffective because of its unfavorable
biochemical and pharmacokinetic properties that limit its entry into cells. However, GSH
prodrugs are able to replenish intracellular GSH levels and have been used as
antioxidants for treatment of conditions associated with reduced GSH levels [42]. There
are two approaches for elevating intracellular GSH levels: GSH prodrugs or GSH co-
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drugs. GSH prodrugs are compounds with better bioavailability that can directly or
indirectly increase intracellular GSH levels. GSH co-drugs consist of GSH covalently
linked to another compound that both improves bioavailability and acts synergistically
with GSH to produce the desired therapeutic effect. [42]. GSH prodrugs can be divided
into different categories: GSH esters, cysteinyl-modified GSH derivatives, and cysteine
prodrugs [42]. The most promising GSH prodrugs are the cysteine prodrugs, Nacetylcysteine (NAC) and N-acetylcysteine amide (NACA) (their structures are shown in
Figure 1.16). N-acetylcysteine (NAC), a thiol antioxidant, has been clinically used to
treat various disorders and is already approved by the FDA (the U.S. Food and Drug
Administration). However, NACA, the amide derivative of NAC, has been shown to be
more effective because of its neutral charge, which increases its ability to permeate cell
membranes and the blood-neural barrier [43]. The protective effect of NACA in eyerelated research will be discussed in Section 1.4.5.

A

B

N-Acetylcysteine amide
N-Acetylcysteine
Figure 1.16 The structures of (A) N-acetylcysteine and (B) N-acetylcysteine amide
(adapted from Tobwala, S. and Ercal, N. [44]).
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1.3. EYE ANATOMY AND PHYSIOLOGY
1.3.1. Eye Anatomy. The eye is made up of three layers of tissues. The
outermost layer is composed of the cornea and sclera. The middle layer contains the
choroid, ciliary body, pigmented epithelium, and iris. The light-sensitive retina is the
innermost layer. The lens focuses an image of the visual world on the retina, which acts
like film in a camera. The macula lies near the center of the retina and is responsible for
high-resolution color vision. The fovea is a small depression at the center of the macula
and enables the highest-resolution vision. Figure 1.17 shows a horizontal section of the
right eye [45]. Once the retina receives light focused by the lens, it converts the light into
electrical signals and then sends these signals through the optic nerve to the brain. When
the macula is damaged, the center of a visual image will be blurry or lost completely [46],
which will affect a patient’s daily activities, such as driving, reading, and recognizing
faces.

Figure 1.17 Horizontal section of the right eye (adapted from Basicmedicalkey [45]).
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1.3.2. Retina. Histologically, the retina has three layers that contain nerve cell
bodies and two layers of synapses (Figure 1.18) [47]. The three nerve cell body layers are
the ganglion cell layer (GCL), inner nuclear layer (INL), and outer nuclear layer (ONL).
These layers are interconnected by two synapses, the inner plexiform layer (IPL) and the
outer plexiform layer (OPL). The GCL contains the bodies of ganglion cells and
displaced amacrine cells; the INL contains the bodies of bipolar, horizontal, and amacrine
cells; and the ONL contains cell bodies of the rods and cones. The IPL functions as a
relay station for the vertical-information-carrying nerve cells, the bipolar cells, to connect
with ganglion cells. In the OPL, rods and cones synapse with both horizontal cells and
bipolar cells. The retinal pigment epithelium (RPE) is a single layer of hexagonal cells
and contains the pigment melanin. The RPE connects retinal cells and the choroid and
forms a part of the blood-retinal barrier. Figure 1.19 shows a color fundus photograph of
a normal macula and a cross-section of macular layers [48].
1.4. AGE-RELATED MACULAR DEGENERATION
1.4.1. What is AMD? Age-related macular degeneration (AMD) is the leading
cause of irreversible blindness in the industrialized world, and the third-leading cause
worldwide [49, 50]. In the U.S, about 2.1 million people are affected by AMD, and the
number of cases is projected to increase to 3.7 million by 2030 [51, 52]. Taking aging (the
major risk factor) into consideration, the expected global prevalence of AMD is expected
to be approximately 196 million by 2020, and rising to 288 million in 2040 [53]. The
prevalence of AMD is close to that of invasive cancers and almost twice that of
Alzheimer’s [54]. This creates an annual direct health care cost of $4.6 billion in the
U.S.[55]. Unfortunately, patients with AMD lose quality of life because they require
assistance with simple daily tasks, such as walking, reading, or driving [56].
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Figure 1.18 A cross-sectional diagram depicting the major structures of the eye is shown
on the left, and an enlarged diagram of the neural retina, underlying the RPE, choroid,
and sclera is shown on the right (adapted from Jarrett, S. and Boulton, M. [47]).

AMD is a degenerative condition that begins in Bruch’s membrane and
progresses to involve the RPE and ultimately the overlying photoreceptors [57]. The
clinical hallmark of AMD is the presence of drusen. AMD is classified as dry (nonexudative, affecting an estimated 85-90% of patients) or wet (exudative, affecting an
estimated 10-15% of patients) clinically. The non-exudative disease is characterized by
RPE death, or geographic atrophy. Attenuation of the overlying photoreceptors, which
are located in the outer nuclear layer, follows the demise of the RPE. The distinguishing
feature of wet AMD is choroidal neovascularization, followed by exudation and
hemorrhaging as the disease worsens. If left untreated, dry AMD may progress to wet [58,
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59]

; however, this can be halted if a therapeutic intervention is initiated early enough

during the course of the disease.
Currently, there is no FDA-approved treatment for dry AMD. The only available
treatment to slow the progression of visual loss in dry AMD includes vitamin and
micronutrient supplementation, cessation of smoking, and dietary modification [60, 61].
Figure 1.19A is a fundus photograph of the normal macula, and Figure 1.19B is a cross
section of retina (after Haemotoxylin and Eosin staining) that shows the multilayer
structure of the macula [48]. Figure 1.20 compares the pathophysiological classification of
age-related macular degeneration [57, 62]. In early AMD, there are a few medium-sized soft
drusen (63-124 microns in diameter) and retinal pigmentary abnormalities. In
intermediate AMD, at least one large (≥ 125 microns in diameter) and more mediumsized drusen are present, as well as geographic atrophy that does not involve the center of
the macula. Advanced non-neovascular AMD is characterized by drusen and geographic
atrophy that extends to the center of the macula. Advanced neovascular AMD is
characterized by choroidal neovascularization and its consequences, including subretinal
fluid, lipid deposition, hemorrhage, and retinal pigment epithelium (RPE) detachment.
1.4.2. Risk Factors for AMD. AMD is a multifactorial disease. The risk factors
include tobacco smoking, white race, genetics (complement factor H), and light exposure
(expecially blue light). AMD is also associated with hypertension, atherosclerosis, fatrich diet, and obesity [63, 64]. Age is the most significant risk factor for AMD, due to the
build-up of oxidation by-products and decrease in antioxidant capacity with age.
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Figure 1.19 A normal macula (a) Color fundus photograph of a normal left macula. (b)
Multilayer structure of a macula (adapted from Handa J.T. [48]).
From top to bottom: NFL, nerve fiber layer; IPL, inner plexiform layer; INL, inner
nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear layer; PR,
photoreceptor layer; RPE, retinal pigment epithelium; BrM, Bruch’s membrane.

Figure 1.20 Fundus photographs and a cross section of H&E stain showing the
histopathological features in different stages of age-related macular degeneration (AMD)
(adapted and modified from Jager, R. D. et al. [57]).
The white arrow indicates the drusen and geographic atrophy; the black arrow indicates
the drusen and Bruch’s membrane degeneration; and the blue arrow shows the subretinal
hemorrhage.
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1.4.3. How Does Oxidative Stress Contribute to AMD? The RPE is a
monolayer of cuboidal and columnar cells which regulate ion and metabolite transport,
phagocytose photoreceptor outer segments (OS), and metabolize the retinol. These cells
also form the outer blood-retinal barrier and thus maintain the extracellular matrix [65].
This complex layer is subject to intense oxidative insult; therefore, oxidative stress plays
an important role in the dysfunction of the RPE and other retinal cells in macular
degeneration.
This level of exogenous oxidative stress is potentiated by the relative paucity of
antioxidants, such as GSH, in an aging retina. Light-induced peroxidation of shed
photoreceptor outer segments, that contain polyunsaturated fatty acids (PUFAs), leads to
the formation of toxic reactive oxygen species (ROS) and lipofuscin. Lipofuscin contains
a fluorescent mixture of lipid-protein complexes, by-products of vitamin A (bisretinoids)
metabolism, and lipid peroxidation products. Lipofuscin is cytotoxic and can activate
complement and increase oxidative stress in RPE. Accumulation of ROS-laden lipofuscin
granules, elevated local oxygen tension, high PUFA content, light exposure, and
secondary photosensitizing agents that accumulate with aging create a highly oxidizing
environment for the RPE [52]. The peroxidation by-product of PUFAs, mainly is
docosahexaenoic acid (DHA) to form carboxyethylpyrrole (CEP), can bind to protein.
The CEP-protein adducts can further lead to activate complement and induce neoangiogenesis. Figure 1.21 shows the resources of oxidative stress and outline the key role
of oxidative stress in AMD pathogenesis [66].
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Figure 1.21 Key role of oxidative stress in AMD pathogenesis (adapted from Nowak, J.Z.
[66]
). POS, photoreceptor outer segment; CEP, carboxyethylpyrrole; DHA,
docosahexaenoic acid.

1.4.4. Treatment and the Results of Age-Related Eye Disease Study
(AREDS). Treatment options for dry AMD are limited. Early AMD is asymptomatic and
often goes untreated until more severe symptoms manifest as the disease progresses. For
intermediate and late dry AMD, the only currently available treatments are aimed at
slowing the progression to advanced AMD and include vitamin and micronutrient
supplementation, cessation of smoking, and dietary modification [60, 61].
In prospective large trials, like the Age-Related Eye Disease Studies (AREDS and
AREDS2), conducted by the U.S. National Eye Institute, a wide variety of nutrients were
studied, including ω-3 fatty acids, antioxidants (β-carotene and vitamins C and E),
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minerals (zinc and copper), and xanthophyll carotenoids (lutein and zeaxanthin) [67, 68].
The first AREDS trial was performed in 1990, and results showed that a combination of
vitamin C (500 mg/day), vitamin E (400 IU/day), β-carotene (25,000 IU)/day), zinc (zinc
oxide, 80 mg/day), and copper (cupric oxide, 2 mg/day) can reduce the risk of late AMD
by 25% [69]. The follow-up ARDES2 study was initiated in 2006, for a period of over 5
years, to evaluate the effects of adding lutein, zeaxanthin, and ω-3 fatty acids to the
original AREDS formulation on progression to advanced AMD. A further modification
of the original AREDS formulation was the elimination of β-carotene because of possible
pro-oxidant activity that could increase lung cancer risk in smokers. The AREDS2
formulas incorporated either lutein and zeaxanthin (10 mg/day and 2 mg/day) or DHA
and EPA (350 mg/day and 650 mg/day) [70]. Compared with results for participants
treated with the original formulation (with β-carotene, but neither lutein nor zeaxanthin),
those who were administered the AREDS2 formulation (with lutein and zeaxanthin but
no β-carotene) had an 18% lower risk of progressing to advanced AMD (95% CI, 0.690.96; P = 0.02) [68, 71].
Exudative AMD is characterized by choroidal neovascular membrane formation.
The available treatments include anti-VEGF therapy (e.g., ranibizumab), macular thermal
laser photocoagulation, and photodynamic therapy (PDT, e.g., Visudyne®) to minimize or
block new blood vessels [72]. For dry AMD, however, there is currently no FDA-approved
treatment. Although numerous investigations of candidate treatments have been
conducted, the results of these studies are inconclusive. Therefore, there is a dire need for
an effective AMD treatment. An ideal therapeutic agent should be highly bioavailable,
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non-toxic, easy to use, and economical. It should also limit oxidation, boost antioxidative mechanisms, and even reverse existing damage.
1.4.5. The Protective Effect of NACA in Eye-Related Research. For more
than a decade, our research group has been investigating the use of thiol antioxidants,
particularly N-acetylcysteine amide (NACA)[73-75], in oxidative stress-related eye
disorders such as cataracts and AMD [43, 76-80]. The immortalized ARPE-19 cell line and
primary cultures of RPE cells were used as in vitro models. ROS generation and lipid
peroxidation induced by tert-butyl hydroperoxide (TBHP) were reversed by pretreatment
with NACA. NACA also protected against TBHP-induced cell damage by increasing
cellular levels of GSH, increasing antioxidant enzyme glutathione peroxidase (GPx)
activity, and maintaining cellular integrity, as measured by transepithelial electrical
resistance (TEER). In an animal model, phototoxicity-induced photoreceptor cell death
and dysfunction were prevented by NACA [77].
1.5. OTHER OXIDATIVE-STRESS RELATED EYE DISORDERS
Oxidative stress and ROS are involved in the pathogenesis of numerous eye
disorders [81, 82], especially in age-related cataract [83], age-related macular degeneration
(AMD), open-angle glaucoma [84], and diabetic retinopathy [85, 86]. They are also
implicated in autoimmune uveitis and pseudoexofoliation syndrome (PEX). Important
features of these diseases and the role of oxidative stress in each will be discussed briefly
in the following section. Table 1.4 summarizes the major risk factors and role of
oxidative damage in oxidative stress-related ocular diseases.
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Table 1.4 Summary of the risk factors of oxidative-stress related ocular diseases and the
role of oxidative stress in pathogenesis of each
Ocular Disorders
-tissue affected

Types

Major Risk Factors

Role of ROS &
Oxidative Damage

Cataract
-lens

Nuclear

Age
Sunlight (UV-B)
UV light
Diabetes
Microwave radiation
-ref: [87]
Age
Tobacco smoking
UV light
High fat diets
Cataract surgery
Complement H
-ref:[63, 88]
High intraocular
pressure
Family history
Age
Thin cornea
Eye surgery
Using corticosteroid
Farsightedness
Genetics

↓ GSH,
↓Antioxidant enzymes
Internal H2O2
↓ Protein sulfhydryl
Crystalline crosslinkage
↓ GSH,
↓Antioxidant enzymes
High oxygen tension
High metabolic activity
High energy light
Photo-oxidative damage
PUFA (↑4-HNE, CEP)
TM oxidative stress
DNA damage
(Mitochondria, TM)
Lipid peroxidation

Diabetes
Hyperglycemia
Hypertension
Dyslipidemia
-ref: [89]

Hyperglycemia
Polyol pathway
(↓ NADPH)
PKA activation

Cortical
Subcapsular
AMD
- Photoreceptor,
RPE, Bruch’s
Membrane,;
neovascularization

Dry
(Geographic
Atrophic)

Glaucoma
-ganglion cells,
optic nerve

Open-Angle
(Partially blocks the
drainage)

Wet (Choroidal
neovascularization)

Angle-Closure
(Iris blocks the
drainage angle)
Retinitis Pigmentosa
(RP)
- photoreceptors
Diabetic retinopathy
(DR)
- macula;
neovascularization
Autoimmune uveitis
-outer segment of
retina
Pseudoexofoliation
syndrome (PEX)
- systemic disease in
the anterior segment
of eye

Rod-cone dystrophy

Non-Proliferative DR
Proliferative DR

High oxygen tension
↓oxygen consumption

PR DNA damage
(mitochondria)
Age

↓GSH
↑MDA in lens epithelial
cell

RPE, retinal pigment epithelium; NPDR, non-proliferative diabetic retinopathy; PDR,
proliferative diabetic retinopathy; 4-HNE, 4-hydroxyl-2-nonenal; CEP,
carboxyethylpyrrole; TM, trabecular meshwork.
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1.5.1. Cataract. A cataract is the progressive opacification of the lens, resulting
in blurred vision. Cataracts are the leading cause of blindness worldwide and account for
42% of all blindness [90]. While the primary cause of cataracts is age, they are also
common in diabetes where superoxide levels in the mitochondria are elevated as a result
of hyperglycemia [90]. Increased serum MDA levels and decreased blood levels of
enzymatic antioxidants SOD and GPx are also indicators of oxidative stress observed in
cataract patients [91]. α-Crystallin, a major protein family in the lens, is responsible for the
maintenance of lens transparency. It has been demonstrated that exposure to UV light
induces cross-linking of α-, β- and γ-crystallins [87]. α-Crystallins can also act as
chaperons against photodamage from UV light [92]. Figure 1.22 shows how aging and
diabetes affect the chaperone function of α-crystallins in cataract formation [92].

Figure 1.22 The possible molecular events affecting chaperone function of α‐crystallins
during aging and diabetes and potential target points for modulation α‐crystallin
chaperone function (adapted from Kumar, P & Reddy G. [92]).
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1.5.2. Glaucoma. In this disease, fluid builds up in the anterior chamber of the
eye, which increases intraocular pressure and results in retinal ganglion cell apoptosis and
damage to the optic nerve. Glaucoma is the second most common cause of blindness
worldwide [84]. The trabecular meshwork (TM) has fewer antioxidant defenses than the
cornea and iris, thus making it the most sensitive tissue to oxidative insult in the anterior
chamber of the eye. There are three key pieces of evidence that suggest TM cells are
subject to a highly oxidizing environment [82, 84]. First, increased hydrogen peroxide
(H2O2) measured in the aqueous humor outflow depletes glutathione [93]. Secondly, the
antioxidant potential in TM tissue from open-angle glaucoma patients was lower than that
in controls [94]. Finally, increased ROS levels (H2O2) have been shown to damage to
mitochondrial DNA in the TM. Oxidative stress, occurring not only in the TM but also in
retinal cells, appears to be involved in the neuronal cell degeneration affecting the optic
nerve in open-angle glaucoma [82, 95]. The oxidation in the TM involved in the
pathogenesis of open-angle glaucoma is shown in Figure 1.23.

Figure 1.23 Key role of oxidative stress in glaucoma pathogenesis.
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1.5.3. Diabetic Retinopathy (DM). Diabetic retinopathy is one of the most
common microvascular complications in diabetes mellitus (DM) patients and is the
leading cause of blindness and visual dysfunction in working-age populations [96, 97].
Hyperglycemia induces ROS production in mitochondria, leading to increased levels of
reactive oxygen metabolites in type 2 DM patients [85]. Hyperglycemia upregulates the
polyol pathway (also called the sorbitol-aldose reductase pathway), resulting in decreased
NADPH available for GR-catalyzed regeneration of GSH from GSSG [86].
Hyperglycemia also activates PKC and contributes to ROS formation. Figure 1.24 shows
the relationship between hyperglycemia and oxidative stress in the pathogenesis of
diabetic retinopathy [86].

Figure 1.24 Relationship between hyperglycemia, oxidative stress, and pathways
associated with the pathogenesis of diabetic retinopathy (adapted from Wu, Y. et al. [86]).
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1.5.4. Retinitis Pigmentosa (RP). RP, also known as rod-cone dystrophy, is an
inherited eye disorder that causes photoreceptor breakdown and retinal degeneration.
Human ONL is composed of 95% rods and 5% cones. Oxidative damage is a major
contributor to cone cell death. Oxygen utilization is greatly reduced after rods die, which
eventually disturbs the oxygen balance in the outer retina. High oxygen tension and
NADPH oxidase activation cause superoxide radical production in both mitochondria and
cytoplasm in cones [98, 99].
1.5.5. Autoimmune Uveitis. The uvea is the layer located between the sclera
and the retina that includes the iris, ciliary body, and choroid. Inflammation during
uveitis is strongly correlated with ROS generation [100]. Oxidative stress caused by DNA
damage in photoreceptor mitochondria likely initiates the pathological effects. Figure
1.25 shows the role of oxidative stress in autoimmune uveitis as well as the effect of
antioxidants in preventing uveitis complications [100].
1.5.6. Pseudoexfoliation Syndrome (PEX). PEX is an age-related fibrillopathy
of the eye. It is characterized by the accumulation of granular material on the anterior
segment structures of the eye and is associated with glaucoma and cataract surgery
complications [81, 101]. Decreased GSH levels and increased lipid peroxidation by-product
malondialdehyde (MDA) levels were found in the lens epithelial cells of PEX patients,
which may indicate oxidative stress involvement in the pathogenesis of this syndrome
[102]

.
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Figure 1.25 Effects of antioxidants in preventing uveitis (adapted from Gartaganis, S.P. et
al. [102]).
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2. EXPERIMENTAL DESIGN

Since oxidative stress is strongly implicated in the pathogenesis of AMD, we
hypothesized that N-acetylcysteine amide (NACA), a novel thiol antioxidant, would
impede the progression of oxidative stress-induced retinal degeneration. We designed an
in vitro and an in vivo model to investigate the effectiveness of NACA in preventing
retinal pigment epithelial cell and retinal cell damage.
In an in vitro model, we tested the ability of NACA to prevent oxidative stress
induced by tert-butyl hydroperoxide in primary human retinal pigment epithelial cells
(HRPEpiC) (Figure 2.1).

Figure 2.1 The experimental hypothesis of NACA’s role in defending RPE cells against
oxidative stress in a cell model.
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In an animal model, we investigated the effectiveness of NACA eye drops in
preventing and/or delaying photoreceptor loss and maintaining visual potential in sodium
iodate-induced retinal degeneration in C57BL/6 mice (Figure 2.2).

Figure 2.2 The experimental hypothesis of NACA’s role in defending against sodium
iodate-induced retinal degeneration in an animal model.

Sodium iodate was first used in 1941 to selectively induce retinal degeneration in
rabbits. Systematic delivery of NaIO3, a stable oxidizing agent, is an effective way to
induce retinal degeneration, with loss of retinal function followed by local morphological
changes in RPE cells and photoreceptors, and significant ONL thinning.
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To study the effectiveness of NACA eye drops in preventing retinal degeneration, we
utilized an animal model with sodium iodate-treated C57BL/6 mice. The details of the
experimental design are outlined in Figure 2.3.

Figure 2.3 Experimental design for sodium iodate-induced retinal degeneration in
C57BL/6 mice.
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3. MATERIALS & METHODS

3.1. MATERIALS
N-acetylcysteine amide (NACA) was provided by Dr. Glenn Goldstein (David
Pharmaceuticals, New York, NY, USA). C57BL/6 mice were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). Other chemicals were ordered from Sigma (St.
Louis, MO, USA), unless otherwise indicated.
Human retinal pigment epithelial cells (HRPEpiC, CAT # 6540) were purchased
from ScienCell Research Laboratories (Carlsbad, CA, USA). HRPEpiC were grown as
suggested by ScienCell, and all experiments were performed during passages 4 and 5.
3.2. CELL CULTURE CONDITIONS
HRPEpiC were grown in complete media and divided in to four groups (control,
NACA, TBHP, and NACA+TBHP). Cells were pretreated with 2 mM NACA (in NACA
and NACA+TBHP groups) or serum-free media (in control and TBHP groups). After 4
hours of incubation, the media was removed, and cells were washed with PBS and then
dosed with 0.5 mM TBHP (in TBHP and NACA+TBHP groups) or serum free media
(control and NACA groups) for 3 hours. For apoptosis assays, an alternative NACA and
TBHP dosing protocol was used in addition to the one described above. This involved
pretreatment with NACA for 1 hour (in NACA and NACA+TBHP groups) prior to
TBHP exposure and addition of NACA (in NACA and NACA+TBHP groups) to the
media for an additional 3 hours while TBHP was applied (i.e., cells were co-exposed to
TBHP and NACA for 3 hours).
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3.3. CELL VIABILITY ASSAY
Calcein-AM is a cell-permeant dye that can be used to determine cell viability in
most eukaryotic cells. In living cells, the non-fluorescent Calcein-AM is converted to
green-fluorescent Calcein after acetoxymethyl ester hydrolysis by intracellular esterases.
The structure of Calcein-AM and its staining mechanism is illustrated in Figure 3.1[103].
Each well of 96-well plate contained 1×104 cells were grown in complete media
for 24 hours before further dosing. After cells were rinsed with 1X PBS (37 °C), cells
were treated as indicated in the experimental design. Each well of cells was replaced with
100 μL of 2 μM Calcein-AM (Biotium Inc., CA, USA) in 1X phosphate buffered saline
(PBS), and cells were incubated for 30 min before measuring the fluorescence by a plate
reader (λex = 485 nm and λem = 530 nm) (FLUOstar Omega, BMG Labtech).

Figure 3.1 Calcein-AM staining mechanism (adapted from Dojindo Molecular
Technologies, Inc. [103]).

38
3.4. INTRACELLULAR REACTIVE OXYGEN SPECIES (ROS)
MEASUREMENT
Cellular ROS accumulation was measured using 5-(and-6)-chloromethyl-2′,7′dichlorodihydrofluorescein diacetate, acetyl ester (CM-H2DCFDA, Molecular Probes,
Life Technologies) [104-106]. CM-H2DCFDA is a chloromethyl derivative of H2DCFDA
(2′,7′-dichlorodihydrofluorescein diacetate; molecular formula: C24H16Cl2O7) and
exhibits better retention in live cells than H2DCFDA. CM-H2DCFDA passively diffuses
into cells, where its acetate groups are cleaved by intracellular esterases, and its thiolreactive chloromethyl group reacts with intracellular glutathione and other thiols.
Subsequent oxidation yields a fluorescent adduct that is trapped inside the cell and can
therefore be detected for extended periods of time, making CM-H2DCFDA a valuable
tool for ROS quantification during a longer-term experimental design. The structure of
CM-H2DCFDA and the mechanism of ROS measurement are illustrated in Figure 3.2.
Each well of 96-well plate contained 1×104 cells were grown with complete
media for 24 hours. CM-H2DCFDA was freshly dissolved in dimethyl sulfoxide (DMSO)
to make 10 mM stock solution, then further diluted in 1X PBS to make working solution
and kept from light exposure. After the cells were rinsed with 1X PBS (37 °C), 100 μL of
10 μM CM-H2DCFDA in 1X PBS (37 °C) were added to each well, and then plates were
placed back to incubator for another 30 min. Each well was rinsed carefully with 1X PBS
to remove extra CM-H2DCFDA after incubation. Cells were dosed with NACA and/or
TBHP in 100 μL of serum-free, phenol red-free media according to the experimental
design. Fluorescence was measured after treatment by a plate reader (λex = 485 nm and
λem = 530 nm) (FLUOstar Omega, BMG Labtech).
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Figure 3.2 The measurement of ROS by CM-H2DCFDA.

3.5. QUANTIFICATION OF INTRACELLULAR GLUTATHIONE (GSH) AND
CYSTEINE LEVELS.
GSH is the primary endogenous antioxidant responsible for redox homeostasis in
endothelial cells. Cells were grown at a density of 1.2×106 cells per 10-cm plate for 24
hours before further treatment. Cell pellets were homogenized in serine borate buffer (pH
= 7.5). Supernatant fractions were collected after centrifugation at 1000 xg at 4 °C for 10
min. GSH was separated and quantified by HPLC with fluorescence detection (Finnigan
Surveyor FL Plus, Thermo Scientific, USA) after derivatization of cell homogenates with
N-(1-pyrenyl) maleimide (NPM) (Figure 3.3) [107-109]. The mobile phase gradient program
used for analysis of cysteine and GSH is shown in Table 3.1.
For derivatization, retinas were homogenized in 230 µL of serine borate buffer
(pH = 7.5). 50 µL of retina homogenate were mixed with 25 µL of serine borate buffer,
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and 225 µL of NPM was added to derivatize at room temperature for 5 min. Finally, 3 µL
of 2 N HCl were added to quench the reaction. Representative separation of a mixed thiol
standards and a retina sample by HPLC are shown in Figures 3.4 and 3.5. GSH level is
then reported in units of nmol/mg protein.

Figure 3.3 Formation of fluorescent NPM-thiol adduct (adapted from Wu, W. et al. [107]).

Table 3.1 Gradient program of mobile phase used in the HPLC separation
Time
Mobile phase A Mobile phase B
Flow rate
(min)
(%)
(%)
(mL/min)
0.0
100
0.7
6.0
100
0.7
6.1
100
1
20.0
100
1
20.1
100
0.7
25
100
0.7
The mobile phase A was composed of 0.05% acetic acid in 70:30 acetonitrile–
HPLC-H2O (vol : vol) in 1 liter of mobile phase.
The mobile phase B was composed of 0.1% o-phosphoric acid and 0.1% acetic
acid in 70:30 acetonitrile–HPLC H2O (vol : vol) in 1 liter of mobile phase.
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Figure 3.4 The above HPLC chromatogram showing the separation of a derivatized
mixed thiol standard.

Figure 3.5 The above HPLC chromatogram showing the separation of a derivatized retina
sample.
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3.6. GLUTATHIONE REDUCTASE (GR) ACTIVITY ASSAY.
Glutathione reductase (GR, EC 1.6.4.2) catalyzes the reduction of glutathione
disulfide (GSSG) to GSH. This assay is based on the reduction of GSSG by NADPH in
the presence of the enzyme. Cells were homogenized in 250 μL of 50 mM Tris-HCl (pH
= 7.5) containing 1 mM EDTA. After centrifugation at 1000 xg for 15 min, the
supernatant fractions were isolated. NADPH, which absorbs light at 340 nm, was added
to each sample. The rate of its oxidation to NADP+ by GR as GSSG is reduced to 2 GSH
can be determined from the resulting decrease in absorbance at this wavelength over time
[110, 111]

.

Reaction mixture:
800 µL of diluted supernatant + 40 µL of 25 mM GSSG + 160 µL of 1.25 mM NADPH
(Proportion of supernatant should be increased if the rate of reduction in NADPH
absorbance, [-ΔA]/min is less than 30 mAbs/min).

GR activity calculation step by step:
The molar extinction coefficient ε for NADPH at 340 nm is 6220 M-1cm-1. The activity of
GR can be calculated according to the Beer-Lambert law as follows:

43
Given: ε = 6220 M-1cm-1 when the path length = 1 cm;
ε = 6.22 x 10-3 (nmol/mL)-1;
1 mU = 1 nmol/min (i.e., 1 mU GR reduces 1 nmol NADPH per min);
Then: mU/mL = (ΔA340/min)/ε, or mU/mL = [A340/min]/[6.22 x 10-3 mL/nmol];
mU/mg = (mU/mL)/(mg/mL protein)
GR activity is then reported in units of mU/mg protein.

3.7. QUANTIFICATION OF TOTAL PROTEIN
Protein levels of the cell homogenates were measured by the Bradford method
[112]

(BioRad Laboratories, Inc., CA, USA) and BCA protein assay [113] (ThermoFisher

Scientific, NY, USA). Bovine serum albumin was used as the protein standard. The
protein concentration is reported in units of mg/mL protein.
The Bradford protein assay, which was performed using Coomassie® Brilliant
Blue G-250, was used for total protein concentrations between 5 mg/mL to 50 mg/mL.
After 20 μL of the protein was mixed with 1 mL of Coomassie® Brilliant Blue G-250
solution, the absorbance shifted from 465 nm to 595 nm when the protein was bound to
the dye.
The bicinchoninic acid assay (BCA assay) was used for total protein
quantification especially when samples with protein concentrations between 0.5 µg/mL to
1.5 mg/mL. The method involved reduction of Cu2+ to Cu+ by protein in an alkaline
solution (Step 1 in Figure 3.6), and formed a purple-colored BCA-Cu+ complex that
absorbs light at 562 nm (Step 2 in Figure 3.6) [114].
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Figure 3.6 Reaction schematic for the BCA protein assay (adapted from ThermoFisher
website [114]).

3.8. DEXTRAN PERMEABILITY AND TRANSEPITHELIAL ELECTRICAL
RESISTANCE (TEER) MEASUREMENT
12-mm Transwell® (Product #3401) inserts were coated with poly-L-lysine for 1
hour prior to seeding with 0.5 mL of cell suspension at 1×106 cells/mL. Each well
contained 1.5 mL of media, and cell growth was maintained for 5 days without disturbing
the monolayer (Figure 3.7). Cells were treated with NACA and/or TBHP according to the
experimental design. After an appropriate time, the treatment media in the insert was
removed and replaced with 250 μL of serum-free, phenol red-free media. The insert was
then relocated to a new plate containing 1.5 mL of fresh serum-free, phenol red-free
media. Fluorescently labelled dextrans (FD4, 1 mg/mL in media, Sigma) were
administered apically onto the insert after dosing. Fluorescence was read after 30 min (λex
= 485 nm and λem = 530 nm) (FLUOstar Omega, BMG Labtech, Cary, NC, USA). The
inserts containing the monolayer were then transferred to new wells with 500 μL of
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serum-free phenol, red-free media and used for TEER measurement. TEER readings
were recorded by an EVOM voltohmmeter (World Precision Instruments, Sarasota, FL,
USA) to assess the integrity of the HRPEpiC monolayer.

Figure 3.7 The monolayer integrity measurement (A) TEER and (B) Dextran
permeability.

3.9. FLOW CYTOMETRY QUANTIFICATION OF APOPTOTIC CELLS
Cell suspension contained 6.5×105 cells were grown in each of 6-cm plates and
dosed as described by the experimental design. To conduct the apoptosis assay,
trypsinized cells were re-suspended in 100 μL of 1X binding buffer containing 5 μL of 7AAD and 5 μL of annexin V-FITC (BD Biosciences, San Jose, CA, USA). Cells were
incubated for 15 min at room temperature in the dark, followed by addition of 250 μL of
binding buffer. The cells were then analyzed using a Cell Lab Quanta SC flow cytometer
(Beckman Coulter, Fullerton, CA, USA).

46
3.10. ANIMAL MODEL AND EXPERIMENTAL DESIGN
Seven-week-old male C57BL/6 mice were received and housed in a temperatureand humidity-controlled (about 22 °C and 55%, respectively) animal facility, with a 12hour light and dark cycle. The animals had free access to rodent chow and water; they
were acclimatized for 1 week before experiments were performed. All animal procedures
conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the Institutional Animal Care and Use Committee of
Missouri University of Science and Technology.
Eight-week-old C57BL/6 mice received 0.1% NACA eye drops (in 25 mM
phosphate buffer, pH 7.4) twice a day, on every other day for 4 weeks. After dosing with
NACA for 4 weeks, mice received one intraperitoneal (IP) injection of 75 mg/kg NaIO3,
and then eye drops were continued for another week.
On the final day of the experiment, the mice were anesthetized by an IP injection
of ketamine (120 mg/kg) and xylazine (16 mg/kg) and cervical dislocation was used for
the secondary euthanasia method. Retinas were removed under a dissecting microscope
and immediately placed in liquid nitrogen immediately for further analysis.
3.11. ELECTRORETINOGRAPHY (ERG)
After adaptation in the dark for 10-12 hours, scotopic and photopic ERG were
recorded in mice under anesthesia induced by isoflurane (Butler Schein, Dublin OH)
(2.25% for induction and 1.25% maintenance). Proparacaine hydrochloride ophthalmic
solution and tropicamide (0.5%, Akorn Inc, IL, USA) were used for the topical anesthetic
and mydriatic, respectively. The recording electrode was placed in a drop of
methylcellulose on the surface of the cornea, a reference electrode was placed
subdermally at the vertex of the skull, and a ground electrode was placed subdermally at
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the base of the tail (Figure 3.8). Scotopic and photopic ERGs [115, 116] were recorded using
an HMsERG machine (OcuScience, Henderson, NV, USA). ERG procedures started with
a scotopic intensity series from -3 to 1 log (cd∙s/m2). Photopic ERGs were recorded after
light adaption (10000 mcd∙s/m2) for 5 min (mcd: millicandelas). The scotopic and
photopic view program is illustrated in Figure 3.9. Signals obtained from corneal surfaces
were amplified, digitized, and averaged using ERG View 2.5 software (Retvet Corp
Ocuscience, Rolla, Missouri).

Figure 3.8 More pictures in conducting electroretinography. (A) The corneal electrode is
placed between contact lenses and the cornea; (B) The placements of corneal electrode
(red), skin electrode (green), and mask to introduce isoflurane; (C) and (D) The
HMsERG system; (E) The isoflurane induction system.

48
Scotopic/Photopic Subset
Flash Intensity

Step label

Action
Test
Delay
Test
Delay
Test
Delay
Test
Delay
Test
Background Light Adaptation
Test
Delay
Test
Delay
Test
Delay
Test
Delay
Test
Delay
Test
Delay
Test
Delay
Test
Delay
Flicker
Test
Flicker
Test

1

Number of
Elapsed
Flashes
Interval Time Req.
Time
Avg’d
Seconds Seconds Seconds response
4
30
90
90
30
120
30
4
30
90
210
30
240
300
4
30
90
330 rod only
30
360
3000
4
30
90
450 mix
30
480
30000
4
30
90
570
10000
300
870
2000
32
0.5
16
886
2
888
2500
32
0.5
16
904
2
906
3000
32
0.5
16
922
2
924
3500
32
0.5
16
940
2
942
4000
32
0.5
16
958
2
960
4500
32
0.5
16
976
2
978
5000
32
0.5
16
994 cone only
2
996
10000
32
0.5
16
1012
2
1014
3000
128
0.033
2
1016
10000
128
0.033
2
1018
Total Elapsed Time in Minutes
16.97
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2
-3
3
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9
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0.25
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0.37
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0.5

14
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0
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Figure 3.9 The program settings for the scotopic and photopic view in an ERG recording.

The ERG is a recording of a light-elicited diffuse electrical responses developed
by cells within the retina [117]. Four different waveforms (a-wave, b-wave, c-wave and dwave) may be observed, depending on the ERG program. The first negative peak was the
a-wave, which was followed by a large, positive b-wave and a slower, positive c-wave.
After termination of the stimulus, a d-wave developed. Figure 3.10 shows where the
major components of the ERG originate. The ERG a-wave (called the “late receptor
potential”) originated from the photoreceptors, and the b-wave originated from the inner
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retinal cells that are post-synaptic to the photoreceptors (Figure 3.10) [118]. The a-wave
and b-wave represented the health of the outer and inner retina, respectively. Analysis of
the ERG waveforms required measurement of the amplitude and the implicit time of each
wave (Figure 3.11) [118]. In the ERG program used for the investigations described here,
only the a-wave and b-wave were recorded and analyzed.

Figure 3.10 Diagram of the retina showing where the major components of the ERG
originate (adapted from Creel, D.J. [115]). (OP, oscillation potential)

A

B

Figure 3.11 Electroretinogram (A) ERG waveform and (B) amplitude and implicit time
measurement of the ERG waveform (adapted from Creel, D.J. [118]).
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3.12. HEMATOXYLIN AND EOSIN (H&E) STAINING
Eyes were enucleated and fixed in 4% paraformaldehyde overnight. Briefly, the
eyes were then embedded in paraffin, and serial 5-μm of sagittal sections of the whole
eye were cut through the cornea to the optic nerve. Paraffin-embedded serial sections of
the retina were deparaffinized with xylene and absolute ethanol, rehydrated with distilled
water, stained with hematoxylin solution, and counterstained with eosin.
3.13. OUTER NUCLEAR LAYER (ONL) THICKNESS MEASUREMENT
In each fixed and H&E-stained eye (n = 3 mice), the ONL thickness was
measured at 40-μm intervals across 400-µm sections of the parafoveal area located 500
µm from the optic nerve head. Images were analyzed at 20X objective magnification
using ImageJ image processing software (Version 1.49, NIH). For every group, ONL
thickness at each interval was averaged, and statistical analysis was performed.
3.14. 4-HYDROXYNONENAL (4-HNE) IMMUNOHISTOCHEMISTRY
STAINING AND QUANTIFICATION
Briefly, serial sections adjacent to those designated for H&E staining were taken
from paraffin-embedded eyes (n = 3 mice). Sections were deparaffinized, rehydrated,
blocked, and incubated overnight at 4°C with an anti-4-HNE antibody (1:100 dilution;
Abcam 46545, MA, USA) using 3,3'-diaminobenzidine (DAB) as the chromogen (which
indicates the presence of 4-HNE as a dark brown stain) and hematoxylin as the
counterstain. Images were examined at 100X objective magnification for quantification
of 4-HNE levels, using ImageJ to determine the proportion of dark brown area to the total
image area in the ONL.
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3.15. SDS-PAGE AND WESTERN BLOT FOR PTEN AND PHOSPHO-PTEN (PPTEN) ANALYSIS.
Protein levels of cell homogenates were measured using the bicinchoninic acid
(BCA) protein assay. 25-μg of the protein samples (n = 3 mice) were separated in
NuPage 12% Bis-Tris gels (Life Technologies, Grand Island, NY). Anti-PTEN (Cat #
9552) and anti-p-PTEN (Ser380/Thr382/383, Cat # 9554) (1:1000 dilutions; Cell
Signaling, MA, USA) were used as the first antibodies, and GAPDH (1:1000 dilution;
Cell Signaling) was used as the dominant housekeeping gene. SuperSignal
Chemiluminescent substrate was used to visualize PTEN bands. The membrane was
stripped after PTEN measurement, and the procedure was repeated for anti-p-PTEN.
SuperSignal West Pico Chemiluminescent substrate and Restore Western blot stripping
buffer were obtained from Thermo Scientific.
3.16. STATISTICAL ANALYSIS
All values are reported as mean ± SD. Statistical analysis was performed using
GraphPad Prism 5 software (GraphPad, San Diego, CA, USA). Statistical significance
was determined by one-way analysis of variance (ANOVA), followed by Tukey’s
multiple comparison tests. Values of P < 0.05 were considered significant. Each
experiment was repeated at least three times, and each time n ≥ 3.
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ABSTRACT

Background: Age-related macular degeneration (AMD) is a leading cause of blindness
in the United States among adults age 60 and older. While oxidative stress is implicated
in the pathogenesis of AMD, dietary antioxidants have been shown to delay AMD
progression in clinical studies. We hypothesized that N-acetylcysteine amide (NACA), a
thiol antioxidant, would protect retinal pigment epithelium and impede progression of
retinal degeneration.
Methods: tert-Butyl hydroperoxide (TBHP) was used to induce oxidative stress in cell
cultures. The goal was to evaluate the efficacy of NACA in an in vitro model of AMD in
primary human retinal pigment epithelial cells (HRPEpiC).
Results: Our data indicates that TBHP generated reactive oxygen species (ROS), which
reduced cell viability, depleted glutathione (GSH) levels, and compromised glutathione
reductase (GR) activity. Pretreatment with NACA significantly reduced ROS generation,
restored GSH levels and GR activity, and recovered transepithelial electrical resistance.
Pretreatment with NACA did not decrease the number of dying cells, as determined by
flow cytometry analysis. However, survival was significantly improved when cells were
co-exposed to NACA and TBHP after a shortened pretreatment period.
Conclusions: Our data suggest that pretreatment with NACA reduces sublethal but not
lethal effects of TBHP in HRPEpiC. NACA significantly improved cell survival when
administered prior to and during oxidative damage similar to that observed in the
development of dry AMD. These results indicate that continuation of a thiol antioxidant
regimen for treatment of AMD is beneficial throughout the course of the disease, and that
NACA is a potent antioxidant that should be further evaluated for this purpose.
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1. INTRODUCTION

Age-related macular degeneration (AMD) accounts for 8.7% of blindness
worldwide, and is a leading cause of blindness in the United States among adults age 60
and older [1-3]. Globally, about 1 in 32 visual impairments and 1 in 15 cases of blindness
are due to macular disease [4]. Dry AMD is a degenerative condition that begins in
Bruch’s membrane and progresses to the retinal pigment epithelium (RPE) and the
overlying photoreceptors resulting in loss of central vision. The RPE is a single layer of
pigment cells lying between the photoreceptors and choriocapillaris. Its functions include
light absorption, epithelial transport, phagocytosis, secretion, and immune modulation.
All of these functions are important for maintaining and supporting the photoreceptors. A
high blood flow rate and high O2 saturation in the choriocapillaris render the RPE more
exposed to oxidative stress [5]. Oxidative stress seems to play a major role in the
pathogenesis of dry AMD and retinal degeneration, although the pathophysiology of dry
AMD is complex [5, 6]. The macula is subject to increased levels of photo-oxidative stress
because of its elevated metabolic rate and high proportion of polyunsaturated fatty acids,
which are highly susceptible to lipid peroxidation. As the RPE cells of the macula age,
the oxidation of lipids and other cellular components result in an accumulation of
indigestible lipofuscin in the lysosomes. The accumulation of lipofuscin granules closely
parallels drusen formation in time and distribution in the retina. Oxidative damage to the
mitochondrial DNA in RPE cells has also been implicated in the development of AMD.
Levels of antioxidants in retinal tissue, glutathione (GSH) in particular, decrease with
aging, making the macula even more vulnerable to progressive oxidative damage [7, 8].
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Endogenous antioxidants, such as GSH, cannot be directly replaced. Instead,
compounds that can easily enter cells and increase intracellular antioxidant levels are
preferred. Dietary antioxidants have been shown to slow the progression of retinal
degeneration and halt progression of AMD in human clinical trials.[9, 10] GSH and its
amino acid precursors protect RPE cells from oxidative injury and oxidant-induced
apoptosis in vitro. N-acetylcysteine amide (NACA), a GSH prodrug, is a promising
candidate for use as an antioxidant-based treatment for AMD. It has demonstrated
efficacy in numerous in vitro and animal models of other oxidative stress-related
conditions, including drug-induced RPE damage and cataracts [11-15]. Our lab has
demonstrated that NACA prevented retinal degeneration in vitro and in animal models
[14]

. The immortalized ARPE-19 cell line was used as an in vitro model because primary

human RPE cells were not available at the time. ROS generation and lipid peroxidation
induced by tert-butyl hydroperoxide (TBHP) were reversed by pretreatment with NACA.
NACA also protected against TBHP-induced cell damage by increasing cellular levels of
GSH, and maintaining cellular integrity, as measured by transepithelial electrical
resistance (TEER). In an animal model, phototoxicity-induced photoreceptor cell death
and photoreceptor dysfunction were prevented by NACA [14].
The experiments reported here utilized primary cultures of human retinal pigment
epithelial cells (HRPEpiC), the best available in vitro model for studying RPE-related
disorders. Because we attempted to mimic a human disease and provide a solution using
a “disease-in-the-dish” model, choosing the most representative cell model was critical.
Thus, we decided to determine whether the beneficial effects of NACA observed in
ARPE-19 cells could also be observed in the HRPEpiC. Our goals were to investigate the
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following: (1) the sub-lethal and lethal effects of TBHP in HRPEpiC and (2) the
protective effects of NACA pretreatment against TBHP-induced oxidative damage.
Sublethal effects included changes in redox status (ROS generation, GSH levels and GR
activity) and monolayer integrity (TEER and dextran permeability). Lethal effects were
determined with cell viability and apoptosis assays.

2. MATERIALS AND METHODS

2.1. MATERIALS
N-acetylcysteine amide (NACA) was provided by Dr. Glenn Goldstein (David
Pharmaceuticals, New York, NY, USA). Human retinal pigment epithelial cells
(HRPEpiC) were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA).
Other chemicals were ordered from Sigma (St. Louis, MO, USA), unless otherwise
indicated.
2.2. HRPEPIC CULTURE AND EXPERIMENTAL DESIGN
HRPEpiC were grown in complete media and divided in to four groups (control,
NACA, TBHP and NACA+TBHP). Cells were pretreated with 2 mM NACA (in NACA
and NACA+TBHP groups) or serum-free media (in control and TBHP groups). After 4
hours incubation, the media was removed, and followed by dosing with 0.5 mM TBHP
for 3 hours. For apoptosis assays, an alternative NACA and TBHP dosing protocol was
used in addition to the one described above. This involved pretreatment with NACA for 1
h prior to TBHP exposure and the addition of NACA for another 3 hours (i.e., the
NACA+TBHP group cells were co-exposed to TBHP and NACA for 3 hours).
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2.3. CELL VIABILITY ASSAY
Cell suspension contained 1×104 cells per well were seeded in a 96-well plate for
24 hours before further dosing. After cells were treated as indicated in the experimental
design, 2 μM Calcein-AM (Biotium Inc., CA) were added to each well, and cells were
incubated for 30 min before measuring the fluorescence by a plate reader (λex = 485 nm
and λem = 530 nm) (FLUOstar Omega, BMG Labtech).
2.4. INTRACELLULAR ROS MEASUREMENT
10 μM of CM-H2DCFDA (Molecular Probes, Life Technologies) were loaded
prior to dosing according to the experimental design. Fluorescence was measured after
treatment (λex = 485 nm and λem = 530 nm).
2.5. QUANTIFICATION OF INTRACELLULAR GLUTATHIONE (GSH)
LEVELS
Cells were grown at a density of 1.2×106 in a 10-cm plate for 24 h before further
treatment. GSH was separated and quantified by HPLC with fluorescence detection
(Finnigan Surveyor FL Plus, Thermo Scientific) after derivatization of cell homogenates
with N-(1-pyrenyl)maleimide (NPM) [16].
2.6. GLUTATHIONE REDUCTASE (GR) ACTIVITY ASSAY
Cells were homogenized in 250 μl of 50 mM Tris-HCl (pH = 7.5) containing 1
mM EDTA. NADPH, which absorbs light at 340 nm, was added to each sample. The rate
of its oxidation to NADP+ by GR as GSSG is reduced to 2 GSH can be determined from
the resulting decrease in absorbance at this wavelength over time [17].
2.7. DETERMINATION OF PROTEIN
Protein levels of the cell homogenates were measured by the Bradford method
(BioRad Laboratories, Inc., CA). Bovine serum albumin was used as the protein standard.
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2.8. DEXTRAN PERMEABILITY AND TRANSEPITHELIAL ELECTRICAL
RESISTANCE (TEER) MEASUREMENT
12-mm Transwell inserts were coated with poly-L-lysine for 1 h prior to seeding
0.5 ml at 1×106 cells/ml. Cell growth was maintained for 5 days without disturbing the
monolayer. Fluorescently labelled dextrans (FD4, 1 mg/ml) were administered apically
onto the insert after dosing. Fluorescence was read after 30 min (λex =485 nm and λem =
530 nm). The inserts containing the monolayer were then transferred to a new well with
serum-free phenol red-free media and used for TEER measurement with an EVOM
voltohmmeter (World Precision Instrument, Sarasota, FL, USA) to assess the integrity of
the HRPEpiC monolayer.
2.9. FLOW CYTOMETRY QUANTIFICATION OF APOPTOTIC CELLS
Cells were grown in 6-cm plates and dosed as described by the experiment design.
Trypsinized cells were re-suspended in binding buffer containing 7-AAD and annexin VFITC (BD Biosciences, San Jose, CA, USA). Cells were incubated for 15 minutes at
room temperature in the dark then analyzed by Cell Lab Quanta SC flow cytometry
(Beckman Coulter, Fullerton, CA, USA).
2.10. STATISTICAL ANALYSIS
All values were reported as mean ± SD (n = 3 to 10). Statistical analysis was
performed using GraphPad Prism 5 software (GraphPad, San Diego, CA, USA).
Statistical significance was determined by one-way analysis of variance (ANOVA),
followed by Tukey’s multiple comparison tests. #, ##, and ### represent P < 0.05, 0.01
and 0.001, respectively, as compared to control; *, **, and ***, which represent P < 0.05,
0.01 and 0.001, respectively, compared to TBHP group.
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3. RESULTS

3.1. TBHP INCREASED INTRACELLULAR ROS LEVELS IN HRPEPIC, AND
NACA PREVENTED ROS GENERATION
To investigate ROS generation in response to TBHP treatment, ROS levels were
measured after exposing cells to TBHP for 3 hours. TBHP induced ROS generation in a
dose-dependent manner (Figure 1A). ROS levels in TBHP-treated cells were 177% of
those observed in the control group (P < 0.001). Pretreatment with NACA decreased
ROS levels to 126% of those observed in the control group (P < 0.001 compared to
TBHP group) (Figure 1B).

Figure 1. Intracellular ROS levels were measured using DCF fluorescence.
(A) TBHP induced ROS generation in a dose-dependent manner. (B) NACA prevented
TBHP-induced ROS generation.
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3.2. DOSE-DEPENDENT GSH DEPLETION BY TBHP AND PREVENTION BY
PRETREATMENT WITH NACA
To elucidate the consequences of elevated ROS in HRPEpiC, GSH levels were
measured after treatment for 3 hours with various concentrations of the TBHP. TBHP
decreased cellular GSH levels in a dose-dependent manner: the average GSH levels in
cells treated with 0, 0.5, 1, 25 and 50 mM of TBHP were 33.4 ± 5.0, 25.1 ± 1.5, 18.9 ±
0.7, 8.8 ± 1.9 and 6.2 ± 1.3 nmol/mg protein, respectively (P < 0.001 compared to
control) (Figure 2A). The protective effect of NACA on GSH depletion in cells treated
with TBHP was also investigated (Figure 2B). GSH is the major antioxidant in a cell and
NACA is a GSH precursor, providing cysteine for GSH synthesis. The average GSH
level in the control group was 31.7 ± 2.3 nmol/mg protein. The GSH level was increased
after NACA incubation (55.1 ± 7.3 nmol/mg protein, P < 0.001 compared to control).
The average GSH level of the TBHP group was 25.1 ± 1.5 nmol/mg protein (P < 0.01
compared to control), but the NACA+TBHP group had an average GSH level of 30.5 ±
2.5 nmol/mg protein (P < 0.05, compared to the TBHP group).

Figure 2. Intracellular GSH levels in HRPEpiC.
(A) TBHP depleted GSH levels in a dose-dependent manner. (B) NACA dramatically
increased intracellular GSH levels and prevented GSH depletion by TBHP.

71
3.3. PRESERVATION OF GLUTATHIONE REDUCTASE ACTIVITY BY
PRETREATMENT WITH NACA
Glutathione reductase (GR), an enzyme that reduces glutathione disulfide to GSH,
is important in restoring intracellular levels of GSH. GR activity was reduced in the
TBHP group (33.5 ± 3.2 versus 21.9 ± 2.2 mU/mg protein in the control group; P < 0.01)
(Figure 3). NACA-pretreated cells exhibited increased GR activity (33.5 ± 5.2 mU/mg
protein; P < 0.01 compared to the TBHP group).

Figure 3. Preservation of glutathione reductase activity by NACA.

3.4. EFFECTS OF OXIDATIVE STRESS ON HRPEPIC MONOLAYER
PARACELLULAR PERMEABILITY AND CONTRIBUTION OF NACA TO
MONOLAYER FUNCTIONAL HOMEOSTASIS
RPE paracellular permeability was assessed in a HRPEpiC grown on a
polycarbonate insert, which formed a monolayer similar to that of the blood-retina barrier

72
in vivo. Transepithelial electrical resistance (TEER) was used as a measure of
paracellular permeability to ions, where lower electrical resistance was evidence of
decreased membrane integrity of a HRPEpiC in the monolayer. Permeability to nonionic molecules was determined based on the amount of dextran that passed through the
monolayer within 30 min. Compared to the TBHP group, the NACA+TBHP group
exhibited significantly greater electrical resistance (Figure 4A). Dextran permeability in
the TBHP group was significantly higher than that of the control (P < 0.05) (Figure 4B).

Figure 4. Protective effects of NACA on paracellular permeability in HRPEpiC.
(A) Results of TEER measurement. (B) Results of dextran permeability assays.

3.5. CELL VIABILITY AND LETHAL EFFECTS OF TBHP ON HRPEPIC
To investigate cell survival in response to ROS generation, cell viability assays
were performed after treatment (Figure 5). Pretreatment with NACA alone did not affect
cell viability (91.1 ± 4.5%), as compared to control (100.0 ± 10.1%). Cell viability was
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reduced in the TBHP group (52.2 ± 5.5%, P < 0.001). Pretreatment with NACA provided
slight but not statistically significant protection against TBHP-induced cell death.

Figure 5. Effects of NACA and TBHP on HRPEpiC cell viability.

3.6. ANNEXIN V-FITC AND 7-AMINOACTINOMYCIN-D (7-AAD) DETECTION
OF APOPTOSIS BY FLOW CYTOMETRY
NACA has multiple antioxidant properties. It is a well-known GSH prodrug and a
free radical scavenger [18-20]. In cell-free systems, NACA can non-enzymatically restore
GSH through thiol-disulfide exchange with the oxidized form, GSSG [21]. An annexin
V-FITC and 7-AAD double staining assay was performed. Cells in the early apoptotic
stages only bound annexin V-FITC, while cells in late apoptotic stages bound both
annexin-V-FITC and 7-AAD. Dead/necrotic cells may only exhibit 7-AAD fluorescence,
due to membrane disintegration and subsequent loss of phosphatidylserine. Table 1
summarizes the percent distribution of viable cells and cells in the early and late stages of
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apoptosis. The percentages of viable cells in the TBHP and NACA+TBHP groups were
very similar (64.0 ± 4.9 % versus 67.8 ± 9.9 %). There was no significant difference in
the number of dying cells (defined as the total of early- and late-stage apoptotic cells)
between the TBHP and the NACA+TBHP groups (20.5 ± 6.1% versus 20.8 ± 4.8%).
Because no significant improvement was observed in the cells pretreated with NACA, the
dosing protocol was modified slightly without changing the total NACA exposure time
(see Methods). Results of the modified treatment protocol are shown in Figure 6 and
Table 2. In the NACA+TBHP (co-exposed) group, the percentage of viable cells (88.6 ±
0.1%) was significantly higher than that in the TBHP group (48.5 ± 5.1%, P < 0.001).
The percentages of dying cells in the TBHP group and the NACA+TBHP co-exposure
group were 16.5 ± 3.6% and 5.5 ± 0.8%, respectively.

Table 1. Percent distribution of viable cells and cells in the early and late stages of
apoptosis after 4 hours of pretreatment with NACA followed by 3 hours of TBHP
exposure.
Groups

Control

2 mM NACA

0.5 mM TBHP NACA+TBHP

Viable cells

94.8 ± 1.3

93.7 ± 0.5

64.0 ± 4.9

67.8 ± 9.9

Early apoptotic cells

1.3 ± 0.6

3.0 ± 1.1

1.8 ± 0.8

2.1 ± 0.4

Late apoptotic cells

1.9 ± 0.2

2.1 ± 0.5

18.8 ± 5.4

18.6 ± 4.9

The results are shown as mean % of total cells ± SD
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Figure 6. Flow cytometry analysis of apoptotic cells following the modified (coexposure) protocol with NACA and TBHP.
The dot plots show a two-parameter analysis of fluorescence intensity of annexin-V FITC
(FL1) and 7-AAD (FL3).

Table 2. Percent distribution of viable cells and cells in the early and late stages of
apoptosis from Figure 6.
Groups

Control

2 mM NACA

0.5 mM TBHP

NACA+TBHP

Viable cells

90.4 ± 1.2

84.8 ± 4.2

48.5 ± 5.1a

88.6 ± 0.0b

Early apoptotic cells

2.2 ± 0.3

1.7 ± 0.9

2.2 ± 1.0

2.3 ± 0.3

Late apoptotic cells

2.5 ± 0.4

4.4 ± 0.2

14.3 ± 3.5

3.1 ± 0.5

The results are shown as mean % of total cells ± SD. (a, P < 0.001 compared to control
group; b, P < 0.001 compared to TBHP group).
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4. DISCUSSION

In this study, we evaluated the potential of NACA to prevent oxidative stressrelated damage in vitro in HRPEpiC. This allowed for evaluation of NACA as a defense
against TBHP-induced oxidative injury. Selection of the best in vitro analogue to RPE in
AMD patients was vital to the clinical relevance of our results. Currently, there are three
cell models being used to study the effects of oxidative stress on the RPE: ARPE-19, fetal
human RPE cells (fhRPE) and primary culture adult human RPE
(e.g., HRPEpiC). ARPE-19 is a spontaneously arising retinal pigment epithelia cell line
derived from normal eyes. The fhRPE and HRPEpiC are primary cultures of fetal
and adult human RPE cells, respectively. When compared to ARPE-19, the fhRPE cells
were healthier; however, adult human RPE were more physiologically representative
of the mature function of RPE than fhRPE [21, 22]. Thus, an adult human primary RPE
cell model was used for the experiments detailed here.
The RPE of the macula is particularly vulnerable to oxidative damage due to
increased O2 exposure, photo-oxidation, elevated metabolic activity, and high proportion
of polyunsaturated fatty acids [5]. Our data demonstrates that TBHP increased ROS levels
in a dose-dependent manner, leading to severe oxidative stress in the HRPEpiC cultures,
and that NACA pre-incubation prevented TBHP-induced ROS production in HRPEpiC.
It has been shown that accumulation of ROS induces severe oxidative stress in RPE cells,
which is manifested by a significant reduction in levels of GSH (the most critical
antioxidant and redox buffer of the cell) [23, 24]. Results from our study showed a
significant decrease in GSH levels in the HRPEpiC, when compared to those of the
control group (Figure 2). Pretreatment with NACA significantly increased GSH levels,
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which may indicate that NACA replenished GSH levels, leading to a reversal of oxidative
stress. The protective effects of NACA are probably mediated by a number of pathways,
which may include supplying cysteine for GSH biosynthesis, reducing extracellular
cystine to cysteine, and converting GSSG to GSH by the action of GR and by nonenzymatic thiol disulfide exchange [12, 25-27]. Our results are in agreement with previous
studies which reported an increase in GSH levels after NACA incubation and a decrease
in GSH levels upon TBHP treatment in an ARPE cell line [11, 14].
Importantly, changes in GR activity were also observed. GR regenerates GSH
from GSSG and plays an important role in GSH homeostasis [28]. NACA treatment
increased the levels of GSH and restored GR activity (Figure 3). Our results are in line
with another study that reported inhibition of GR activity in HepG2 upon TBHP
treatment [29].
In the retina, the RPE forms the blood-retinal barrier (BRB) with tight junctions
that control the exchange of nutrients and metabolites between the retina and the
underlying choriocapillaris. It is thought that oxidative stress may induce changes in the
BRB, which may contribute to the pathogenesis of retinal degeneration. To investigate
and determine the ability of NACA to preserve the BRB function, membrane integrity
after TBHP exposure was evaluated using dextran permeability and TEER assays [30].
NACA prevented TBHP-induced reduction in TEER, verifying its ability to protect
cellular homeostasis and outer BRB integrity under severe oxidative stress conditions. A
similar decrease in TEER has been reported in another study, where human embryonic
stem cell (hESC)-derived RPE cells and ARPE-19 cells were exposed to hydrogen
peroxide [30, 31]. These results are also in agreement with a previous study performed in
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our laboratory using the ARPE-19 [14]. However, we did not observe any significant
difference in dextran permeability upon NACA treatment, which could be due to a lower
sensitivity of dextran permeability when compared with TEER [32].
The decline in GSH observed created a redox imbalance that enhanced cell
susceptibility to injury and ROS-induced apoptosis. Altering the redox state to a more
reduced environment by addition of GSH has been shown to decrease sensitivity of RPE
cells to apoptosis from ROS [33, 34]. We initially investigated the protective effect of
NACA pretreatment by studying cell viability. However, no significant improvement was
noted by either the Calcein-AM or flow cytometry assay in cell survival. Therefore, we
modified our study design to co-exposure along with pre-incubation and dramatically
improved cell survival (Figure 6). It is possible that pretreatment alone is not sufficient to
address multiple oxidative stress-related apoptotic mechanisms. Oxidants, such as
TBHP, may induce apoptosis through two different pathways: (1) Fas-Fas
ligand activation and (2) mitochondrial damage and subsequent release of cytochrome c
[35]

. Because the interplay between these two pathways is complex, it is plausible

that antioxidant treatments, while producing a more favorable redox status in a
cell, may not fully address both apoptotic pathways. In addition, the concentrations of
TBHP (0.5 mM) and NACA (2 mM), used in our investigation, may have been too high
and low, respectively, so that pretreatment with NACA did not provide any significant
cytoprotection. Our previous studies with ARPE-19 indicated that up to 10 mM of NACA
may be used for beneficial effect as a pretreatment for 0.4 mM tBHP exposure [14].
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5. CONCLUSION

This study demonstrated that treatment of retinal pigment epithelium with NACA
protects against oxidative stress-induced cellular injury. NACA also inhibited oxidative
stress-related breakdown of the blood-retinal barrier as measured by TEER. The proposed
mechanism of action involves NACA scavenging existing reactive oxygen species and
increasing levels of reduced glutathione. With the prevalence of AMD and other retinal
degeneration disorders that are expected to double in the coming decades, the
development of more effective therapies to prevent their progression is imperative. Our
results indicate that NACA has the potential to become an effective therapeutic agent by
enhancing antioxidant defenses while removing pathologically relevant ROS.
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AMD, Age-related macular degeneration; 7-AAD, 7-aminoactinomycin-D; AREDs, agerelated eye diseases; GPx, glutathione peroxidase; GR, glutathione reductase; GSH,
glutathione; GSSG, reduces glutathione disulfide; HRPEpiC, primary human retinal
pigment epithelial cells; NACA, N-acetylcysteine amide; NPM, N-(1-pyrenyl)maleimide; ROS, reactive oxygen species; RPE, retinal pigment epithelium; TBHP, tertbutyl hydroperoxide; TEER, transepithelial electrical resistance.

SUMMARY

1.

TBHP increased intracellular ROS levels in HRPEpiC, and NACA prevented ROS
generation.

2.

Dose-dependent GSH depletion by TBHP was prevented by pretreatment with
NACA.

3.

Pretreatment with NACA preserved of GR activity.

4.

NACA inhibited oxidative stress-related breakdown of HRPEpiC monolayer
paracellular permeability.

5.

NACA significantly improved cell survival when administered prior to and during
oxidative damage.
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ABSTRACT

Oxidative stress is considered to be a major factor in the development of agerelated macular degeneration (AMD), and the neuroretina is more sensitive to oxidative
insult when compared to the retinal pigment epithelium (RPE). We hypothesized that Nacetylcysteine amide (NACA) would protect the neuroretina and retard progression of
retinal degeneration. Sodium iodate (NaIO3)-treated C57BL/6 mice were used to evaluate
the therapeutic potential of NACA eye drops by assessing visual and photoreceptor
function through electroretinogram (ERG) and measurements of the outer nuclear layer
(ONL) thickness, the phosphatase and tensin homolog deleted on chromosome ten
(PTEN), and oxidative stress parameters (such as glutathione (GSH), cysteine, and 4hydroxynenal (4-HNE) levels). Our results indicated that NACA eye drops partially
prevented the reduction in the ERG waveform peak amplitudes measured 36 hours after
NaIO3 injection. Furthermore, NACA eye drops prevented reduction in ONL thickness.
Significant increases in GSH, cysteine, 4-HNE, and PTEN were observed, but were
reversed upon treatment with NACA eye drops in this animal model. These results
illustrated that NACA eye drops partially prevent photoreceptor degeneration and loss of
visual potential 36 hours after NaIO3 injection. Accordingly investigations of this potent
antioxidant as a treatment for AMD should definitely be continued.
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1. INTRODUCTION

Age-related macular degeneration (AMD) is the leading cause of irreversible
blindness in the industrialized world and the third leading cause worldwide [1]. This
creates an annual direct health care cost of $4.6 billion in the U.S. [2]. Unfortunately,
patients with AMD lose quality of life, as they need assistance in their daily tasks of
simply walking, reading, or driving [3].
AMD is a complex disease affected by senescence, genetic predisposition,
environmental factor, and oxidative stress, all of which may contribute to its pathogenesis
[4, 5]

. AMD preferentially affects the macula—the central region of the retina. Due to its

high oxygen tension, high metabolic rate, and a greater proportion of polyunsaturated
fatty acids (PUFAs), the macula is subject to increased levels of photo-oxidative stress [69]

. The endogenous antioxidants, such as GSH, in the retinal tissue support the redox

balance that is crucial to maintaining healthy retinal pigment epithelial (RPE) cells and
normal function of the eye [10]. Exogenous oxidative stress is potentiated by the relative
paucity of antioxidants in an aging retina. Light-induced peroxidation of shed
photoreceptor outer segments containing PUFAs leads to the formation of toxic reactive
oxygen species (ROS) and lipofuscin [11-13]. AMD is classified as dry (non-exudative) or
wet (exudative) clinically. Non-exudative disease is characterized by RPE death, or
geographic atrophy. Attenuation of the overlying photoreceptors, which are located in the
outer nuclear layer, follows retinal pigment epithelial demise. The distinguishing feature
of wet AMD is choroidal neovascularization, followed by exudation and hemorrhaging as
the disease worsens. If left untreated, dry AMD may progress to wet [14, 15]; however, this
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can be halted if a therapeutic intervention is initiated early enough during the course of
the disease.
Research efforts, using antioxidants to treat AMD, are plentiful because oxidative
stress is one of the most important causes of AMD [16, 17]. Currently, the only available
treatment to slow the progression of visual loss in dry AMD includes vitamin and
micronutrient supplementation, cessation of smoking, and dietary modification [18, 19]. In
large prospective trials, like the Age-Related Eye Disease Study (AREDS), a wide variety
of nutrients, such as vitamins, ω-3 fatty acids, antioxidants (β-carotene and vitamins C
and E), zinc, lutein, and zeaxanthin were studied [5, 20]. The results of these studies were
inconclusive; therefore, there is a dire need to develop an effective treatment for AMD.
An ideal therapeutic agent should be highly bioavailable, non-toxic, easy to use,
economical, and should limit oxidation, boost anti-oxidative mechanisms, and even
reverse existing damage. One such candidate is N-acetylcysteine amide (NACA), a thiol
antioxidant that has demonstrated beneficial effects on oxidative-stress related eye
disorders [21-25]. Because AMD has a multifactorial etiology, no single animal model can
fully recapitulate all of its pathologic features. Sodium iodate (NaIO3), a stable oxidizing
agent, was first used in a model of retinal degeneration by Sorsby in 1941 [26]. Since then,
the systemic exposure of NaIO3 has been an effective way to induce retinal degeneration
and retinal pigment epithelium atrophy. Thus this model was a very appropriate model to
use for evaluating therapeutic approaches to retinal degeneration [27]. NaIO3 induces both
retinal pigment epithelium degeneration and altered neurosensory function via separate
cell-death pathways: necrosis in RPE and caspase-dependent apoptosis in photoreceptors
[28-30]

. Surprisingly, the photoreceptors seemed more vulnerable to oxidative insult, as
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compared to RPE [29]. Other studies have suggested that necroptosis is a major
mechanism for RPE cell death in response to oxidative stress in the AMD and apoptosis
is the major mechanism for photoreceptor cell death in response to oxidative stress [31, 32].
Because the pathogenic mechanism of the AMD still remains unclear, antioxidants have
garnered much interest in laboratory and clinical studies [18, 33, 34].
The tumor suppressor PTEN (phosphatase and tensin homolog deleted on
chromosome 10) has three primary functions: cell adhesion and lipid phosphatase as well
as protein phosphatase activities. PTEN plays a critical role in the organization of RPE
cell junctions and adhesion [35]. The phosphatase activity of PTEN can recover junctional
β-catenin and can suppress the epithelial-to-mesenchymal transition, thereby inhibiting
the cell migration associated with the onset of retinal degeneration. The catalytic activity
of PTEN is modulated by ROS. The presence of oxidants in the cellular environment can
lead to inactivation of PTEN by phosphorylation, which disturbs the RPE adhesion
structure and initiates RPE degeneration. In an advanced tumor cell, free fatty acidinduced oxidative stress is mediated by phosphorylates PTEN and suppression of PTEN
monoubiquitination, which results in nuclear export of PTEN [36]. PTEN inactivation and
the resulting Akt activation are inhibited by antioxidant treatment [37]. PTEN also
regulates retinal interneuron morphogenesis and synaptic layer formation [38]. In
summary, PTEN is strongly linked with ROS and PI3K/Akt cell survival signaling
pathways.
Ercal’s group has extensively investigated the use of thiol antioxidants,
particularly NACA, in oxidative stress-related eye disorders including cataracts and lightinduced retinal degeneration [21-23, 25, 39]. Their results showed that NACA restored GSH
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levels and activities of glutathione reductase (GR), glutathione peroxidase (GPx) and
catalase in L-buthionine-(S, R)-sulfoximine (BSO)-induced cataracts in rats [21]. NACA
maintained outer nuclear layer thickness and RPE cell integrity in mice exposed
phototoxic light [23]. In previous eye-related investigations, NACA was given as an
injection; however, an eye drop formulation would be more desirable and more
conveniently administered in both a clinical setting and by patients themselves.
Accordingly, this study was designed to formulate a type of NACA eye drops that can be
more conveniently administered in real-life cases, to protect the neuroretina against
oxidative stress-induced damage. An understanding of the protective role of NACA
would help in development of NACA eye drops for treatment of oxidative stress-related
retinal diseases.

2. MATERIALS AND METHODS

2.1. MATERIALS
N-acetylcysteine amide (NACA) was provided by Dr. Glenn Goldstein (David
Pharmaceuticals, New York, NY, USA). C57BL/6 mice were obtained from the Jackson
Laboratory (Bar Harbor, ME, USA). Other chemicals were ordered from Sigma (St.
Louis, MO, USA), unless otherwise indicated.
2.2. ANIMAL MODEL AND EXPERIMENTAL DESIGN
Seven-week-old male C57BL/6 mice were received and housed in a temperatureand humidity-controlled (about 22°C and 55%) animal facility, with a 12-hour light and
dark cycle. The animals had free access to rodent chow and water, and animals were
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acclimatized for 1 week before experiments were performed. All animal procedures
conformed to the ARVO Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the Institutional Animal Care and Use Committee of
Missouri University of Science and Technology.
Eight-week-old C57BL/6 mice received 0.1% NACA eye drops (in 25 mM
phosphate buffer, pH = 7.4) or phosphate buffer bilaterally twice a day, every other day
for 4 weeks. After dosing with NACA for 4 weeks, the mice received one intraperitoneal
(IP) injection of 75 mg/kg NaIO3, and then eye drops were continued for another week.
On the final day of the experiment, mice were anesthetized by an IP injection of
ketamine (120 mg/kg) and xylazine (16 mg/kg), and cervical dislocation was used for the
secondary euthanasia method. Retinas were removed under a dissecting microscope and
immediately placed in liquid nitrogen for further analysis.
2.3. ELECTRORETINOGRAPHY (ERG)
After adaptation for 10-12 hours in the dark, ERGs were recorded in mice under
anesthesia induced by isoflurane [40] (Butler Schein, Dublin OH) (2.25% for induction
and 1.25% maintenance). Mice were placed on a heating pad to maintain their body
temperature during anesthesia. Proparacaine hydrochloride ophthalmic solution and
tropicamide (0.5%, Akorn Inc, IL, USA) were used as the topical anesthetic and
mydriatic, respectively. The recording electrode was placed in a drop of methylcellulose
on the surface of the cornea, a reference electrode was placed subdermally at the vertex
of the skull, and a ground electrode was placed subdermally at the base of the tail.
Scotopic and photopic ERGs were recorded and processed using a HMsERG LAB
system and ERGView 2.5 analytical software [41] (OcuScience, Henderson, NV, USA).

92
ERG procedures started with a scotopic intensity series from -3 to 1 log (cd∙s/m2).
Photopic ERGs were recorded after light adaption (10000 mcd∙s/m2) for 5 min (mcd:
millicandelas).
2.4. HEMATOXYLIN AND EOSIN (H&E) STAINING
Eyes were enucleated and fixed in 4% paraformaldehyde overnight. Briefly, the
eyes were then embedded in paraffin, and serial 5 µm sagittal sections of the whole eye
were cut through the cornea to the optic nerve. Paraffin-embedded serial sections of
retina were deparaffinized with xylene and absolute ethanol, rehydrated with distilled
water, stained with hematoxylin solution, and counterstained with eosin.
2.5. OUTER NUCLEAR LAYER (ONL) THICKNESS MEASUREMENT
In each fixed and H&E-stained eye (n = 3 mice), ONL thickness was measured at
40-μm intervals across 400-µm sections of the parafoveal area, located 500 µm from the
optic nerve head. Images were analyzed at 20X objective magnification using ImageJ
image processing software (Version 1.49, NIH). For every group, ONL thickness at each
interval was averaged, and statistical analysis was performed.
2.6. 4-HYDROXYNONENAL (4-HNE) IMMUNOHISTOCHEMISTRY STAINING
AND QUANTIFICATION
Briefly, serial sections adjacent to those designated for H&E staining were taken
from paraffin-embedded eyes (n = 3 mice). Sections were deparaffinized, rehydrated,
blocked, and incubated overnight at 4°C with anti-4HNE antibody (1:100 dilution;
ab46545, Abcam, MA, USA) using 3,3'-Diaminobenzidine (DAB) as the chromogen
(which indicates the presence of 4-HNE as a dark brown stain) and hematoxylin as the
counterstain. Images were examined at 100X objective magnification for quantification
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of 4-HNE levels, using ImageJ to determine the proportion of dark brown area to the total
image area in the ONL.
2.7. MEASUREMENT OF INTRACELLULAR GLUTATHIONE (GSH) AND
CYSTEINE LEVELS
Mice (n = 5) were sacrificed and eyes were enucleated and dissected under a
dissection microscope to verify isolation of the retina without RPE contamination. The
retinas were homogenized in 250 µL of cold serine borate buffer (pH 7.5). GSH and
cysteine were separated and quantified by HPLC with fluorescence detection (Finnigan
Surveyor FL Plus, Thermo Scientific, USA) after derivatization with N-(1pyrenyl)maleimide (NPM) [42-44]. Protein levels of the homogenates were measured by the
Bradford method [45] (BioRad Laboratories, Inc., CA, USA).
2.8. SDS-PAGE AND WESTERN BLOT FOR PTEN AND PHOSPHO-PTEN (PPTEN) ANALYSIS
Protein levels of the cell homogenates were measured by bicinchoninic acid
(BCA) protein assay. 25 μg protein samples (n=3 mice) were separated in NuPage 12%
Bis-Tris gels (Life Technologies, Grand Island, NY). Anti-PTEN (Cat # 9552) and antip-PTEN (Ser380/Thr382/383; 1000 dilutions; Cat # 95541, Cell Signaling, MA, USA)
were used as the first antibody, and GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) (1:1000 dilutions; Cell Signaling) was used as the dominant
housekeeping gene. SuperSignal Chemiluminescent Substrate was used to visualize
PTEN bands. Membrane was stripped after PTEN measurement, and the procedure was
repeated for anti-p-PTEN. SuperSignal West Pico Chemiluminescent Substrate and
Restore Western blot stripping buffer were obtained from Thermo Scientific.
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2.9. STATISTICAL ANALYSIS
All reported values were represented as the mean ± SD (n ≥ 3). Statistical analysis
was performed using GraphPad Prism 5.01 software (GraphPad Software Inc., La Jolla,
CA). Statistical significance was ascertained by one-way analysis of variance (ANOVA)
and Tukey’s multiple comparison tests. Statistical significance was set at P < 0.05 (*, P <
0.05; **, P < 0.01; ***, P < 0.001).

3. RESULTS

3.1. PARTIAL PREVENTION OF SODIUM IODATE-INDUCED VISUAL LOSS
BY NACA
In order to investigate the effect of NACA on NaIO3-induced retinal dysfunction,
electroretinography was performed 36 hours and 6 days after a NaIO3 injection. Figure 1
is a subset of data in scotopic view at 3000 mcd∙s/m2 showing the mixed rod and cone
response. Figure 1A is the average of the subset ERG data obtained 36 hours after NaIO3
IP injection. Figure 1B-1F shows the data from day 6. The first negative peak was the awave, which was followed by the large, positive b-wave. The a-wave and b-wave
represent the health of outer and inner retina, respectively. The a- and b-wave amplitude
were attenuated and the implicit time prolonged in the aged eye. The average a-wave
amplitudes in the control and NACA groups were 220.0 μV and 187.5 μV, respectively.
Application of NaIO3 led to a significant reduction in all ERG waveform peak amplitudes
and increased a-wave implicit time. The average a-wave amplitude in the NaIO3 group
was 12.4 μV. In contrast, the mean a-wave amplitude measured in the NACA+NaIO3
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group was 181.7 μV. However, the a-wave implicit times were increased in both NaIO3
and NACA+NaIO3 groups. On day 6, the a-wave amplitude in the control, NACA, NaIO3
and NACA+NaIO3 group were 203.5 ± 28.7, 261.3 ± 26.3, 43.9 ± 17.6 and 27.4 ± 11.0
μV, respectively. The b-wave amplitude in the control, NACA, NaIO3 and NACA+NaIO3
group were 377.0 ± 54.7, 501.7 ± 80.7, 47.2 ± 21.8 and 19.0 ± 4.7 μV, respectively. The
average of a- and b-wave amplitude and implicit time are shown in Figure 1C-1F.
3.2. NACA PREVENTS OXIDATIVE DAMAGE AND OUTER NUCLEAR
LAYER (ONL) THINNING
To investigate the ability of NACA eye drops to prevent photoreceptor death, the
thickness of the ONL, which contains rod and cone cell bodies, was measured.
Representative images of H&E-stained retinal sections are shown in Figure 2A, and the
averaged ONL thickness is shown in Figure 2B. In the NaIO3 group, significant loss of
RPE and associated photoreceptor disorganization were observed. The outer segment
layer of rods and cones was markedly reduced, and the boundary between the inner and
outer segments (IS and OS) was lost. ONL folding and thinning were also detected. The
averages of the ONL thickness in the control and NACA groups were 54.48 ± 3.32 and
55.7 ± 4.97 μm, respectively. The ONL thickness was significantly reduced in the NaIO3
group (32.96 ± 4.12 μm) as compared to the control group, but NACA eye drops
significantly prevented ONL thinning (43.87 ± 7.89 μm) (***, P < 0.001).
3.3. EFFECTS OF NAIO3-INJECTION AND NACA EYE DROPS ON RETINAL
GSH AND CYSTEINE LEVELS
To determine the effects of oxidative stress, retinal tissues (n = 5) were dissected
and collected on day 7 after injection of NaIO3 in order to measure GSH and cysteine
levels. GSH levels (Figure 3A) in the sodium iodate group were slightly increased (26.0 ±
1.1 nmol/mg protein) compared to the control group (23.5 ± 0.9 nmol/mg protein) (P <
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0.001). The GSH levels in the NACA group were 22.4 ± 1.1 nmol/mg protein, which
was close to the control group. The cysteine levels (Figure 3B) in the control, NACA,
NaIO3 and the NACA+NaIO3 groups were 0.6 ± 0.1, 0.5 ± 0.1, 5.6 ± 1.1 and 4.0 ± 1.2
nmol/mg protein, respectively. The cysteine levels in the NaIO3 group were significantly
higher than in both the control and NACA groups (P < 0.001).

Figure 1. Partial prevention of sodium iodate-induced retinal dysfunction.
A represents ERG subset data in scotopic view at 3000 mcd∙s/m2 showing mixed rod and
cone response (n = 4-6). A) ERG data were obtained 36 hours after NaIO3 IP injection.
The a-wave and b-wave amplitudes were decreased and the implicit time was prolonged
in the NaIO3-only group. Pretreatment with NACA eye drop partially prevented
reductions in all ERG waveform peak amplitudes when compared to the NaIO3-treated
group. B) ERG data were collected on day 6 after NaIO3 injection (one day before
sacrifice). A-wave and b-wave are attenuated in the NaIO3 group. (C-F) Data analysis of
(B): (C) a-wave amplitude. (D) a-wave implicit time. (E) b-wave amplitude. (F) b-wave
implicit time. NACA eye drops failed to protect photoreceptor function at day 6.
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A

B

Figure 2. NACA prevents oxidative damage and outer nuclear layer thinning.
(A) A representative image of H&E staining for retinal sections showing prevention of
ONL thinning by NACA eye drop (A double-headed arrow indicates the ONL).
(B) Average ONL thickness for each treatment group (n = 3 mice).

Figure 3. Thiol levels in retina.
(A) GSH levels (n = 5) (B) Cysteine levels (n = 5)
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3.4. REDUCTION OF LIPID PEROXIDATION BY-PRODUCT 4-HNE BY NACA
IN ONL
To evaluate the ability of NACA to prevent lipid peroxidation, retinal samples
were stained for 4-HNE adducts by immunohistochemistry. A representative image of the
4-HNE stain is shown in Figure 4A. A greater proportion of brown color in a given area
indicated more 4-HNE adduct formation as demonstrated in Figure 4B. The averages (n =
4) of 4-HNE adduct-stained areas relative to the total stained area in each group were as
follows: 0.49 ± 0.03 in the control group, 0.47 ± 0.05 in the NACA group, 0.67 ± 0.03 in
the NaIO3 group, and 0.5 6± 0.05 in the NACA+NaIO3 group. The 4-HNE levels were
significantly increased in the NaIO3 group (P < 0.01, compared to control) and decreased
in the NACA+NaIO3 group (P < 0.05, compared to NaIO3 group).

A

B

Figure 4. Reduction of lipid peroxidation by-product formation in ONL
(A) Immunohistochemical detection of 4-HNE adducts in retina (40X objective).
(B) Quantification of 4-HNE levels in ONL (A double-headed arrow indicates the ONL)
(n = 3).
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3.5. PTEN AND PHOSPHORYLATED-PTEN (P-PTEN) IN THE RETINA
In order to evaluate the PTEN and phosphorylated PTEN (p-PTEN) levels in the
retina of mice treated with NaIO3, PTEN and p-PTEN were analyzed using the Western
blot. Figure 5A and 5B show the Western blot and the quantitated results for PTEN and
p-PTEN, respectively. The calculated PTEN/p-PTEN ratio is shown in Figure 5C.
PTEN levels in the NaIO3 group were 1.22 times greater than the control, and the
NACA+NaIO3 group PTEN levels were 1.07 times greater than the control. The p-PTEN
levels were increased in the NaIO3-injected group but not significantly when compared
with the control group; however, p-PTEN levels were significantly lower in the
NACA+NaIO3 group (P < 0.05). The average of PTEN/p-PTEN ratio in control, NACA,
NaIO3 and NACA+NaIO3 group were 1.003, 0.98, 1.12 and 1.23, respectively. The
PTEN/p-PTEN ratio in the NACA+NaIO3 group was significantly higher (P < 0.05).

Figure 5. PTEN and phosphorylated-PTEN (p-PTEN) in the retina.
Western blots and quantitated results for PTEN (A), p-PTEN (B). (**, P < 0.01 and *, P
< 0.05) (n = 3).
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Figure 6 The calculated PTEN/p-PTEN ratio from Figure 5.

4. DISCUSSION

NaIO3-induced retinal degeneration in a C57BL/6 mouse model was used to
investigate the effects of NACA eye drops as treatment for oxidative stress-induced
retinal degeneration. NaIO3 is a stable oxidizing agent that has been employed in many
retinal degeneration studies, and systemic administration has been reported to selectively
impair the RPE, which leads to loss of photoreceptors [46]. However, NaIO3 can also
directly impair the neuroretina in vitro and in vivo models [29, 47], and the neuroretina
seems to be more vulnerable to NaIO3-induced damage compared to the RPE in vivo [29].
The underlying molecular mechanisms of NaIO3 toxicity include activation of Akt,
reduction in RPE-specific protein (RPE65), accumulation of ROS in mitochondria,
impairment of Nrf2 signalling, and inactivation of PTEN in cell adhesion [27, 29, 35]. In a
C57BL/6 model, systemic exposure to NaIO3 at low concentrations can induce rapid
dysregulation of phototransduction genes in the neuroretina, including Rho, OPn1mw,
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and Pde6b, as well as reduction in a- and b-wave amplitudes by day 3 and total loss by
day 8 at higher concentrations [29].
N-acetylcysteine (NAC), a thiol antioxidant, has been used clinically to treat
various disorders and is already approved by the FDA (the U.S. Food and Drug
Administration). However, NACA, the amide derivative of NAC, has been shown to be
more effective because of its neutral charge, which increases its ability to permeate cell
membranes and the blood-neural barrier [48]. Independent research with NACA has
demonstrated its improved penetration of cell membranes as compared to other
antioxidants including NAC, vitamin E and carotenoids [49, 50]. This potent antioxidant
functions by directly scavenging free radicals and indirectly by providing cysteine for
GSH synthesis, substituting itself for depleted GSH, and chelating Cu2+ that can catalyze
ROS formation [51]. From the literature, NACA possesses antioxidant, anti-apoptotic, and
anti-inflammatory properties [48]. As an antioxidant, NACA can scavenge radicals,
chelate Pb(II), and participate in thiol-disulfide exchange between GSSG and NACA to
replenish GSH in vitro [39, 49, 52, 53].
In our study, visual function was assessed using the flash electroretinography
(ERG), a non-invasive method [54]. Using this model, we demonstrated that NACA
partially maintained visual function for a short time after administration of a high dose of
NaIO3 (75 mg/kg), but it was unable to halt progression of retinal degeneration for the
duration of the experimental time period. The subset of ERG in the scotopic view at
3000 mcd∙s/m2 represented a combined rod and cone response. The first negative a-wave,
also called the “late receptor potential,” was generated by photoreceptor
hyperpolarization and reflected the general physiological health of the photoreceptors in
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the outer retina [55]. In contrast, the following positive b-wave reflected the health of the
inner layers of the retina, including the ON bipolar cells and the Muller cells [46, 56, 57].
Our data demonstrated that NaIO3 significantly impaired photoreceptor hyperpolarization
and post-phototransduction (Figure 1A-1B) and that NACA eye drops partially prevented
this loss of visual function 36 hr after NaIO3 injection. By the end of the study, however,
NACA eye drops failed to prevent visual function loss. ROS can activate STAT3 (a
transcription factor), which induces rhodopsin degradation via the ubiquitin-proteasome
system. The resulting visual function impairment manifests as subnormal a-wave and bwave measurements, which other research has shown [58-61]. NaIO3 can damage the
synapse between photoreceptors and depolarized bipolar cells, which results in a
diminished ERG b-wave [29, 62].
ONL thickness was used as a metric for photoreceptor cell health. NaIO3-induced
damage to the outer segment (OS) and inner segment (IS) may explain the diminished awave and b-wave in our ERG results. NACA eye drops prevented the NaIO3-induced
thinning of the ONL, verifying its ability to partially preserve visual function as
determined by ERG; however, the NaIO3-induced RPE damage did not improve with
NACA eye drops (Figure 2A).
GSH is the most abundant and critical antioxidant and redox buffer of the cell,
and fluctuations in GSH levels following oxidative insult are largely dependent on the
anti-oxidative capacity of the cell and time course of its response [63-65]. In this study GSH
was found to be increased in the NaIO3 group, which may have been the result of
initiation of cellular defense against oxidative stress. There are many examples of GSH
up-regulation under oxidative stress [25, 66, 67]. In addition to the altered GSH level, a
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significant increase in the cysteine level was observed in the NaIO3 group. This may have
contributed to the rise in GSH levels, as cysteine availability is the rate limiting factor for
GSH synthesis. The age of the of animals used in our study may also have affected GSH
levels, due to their increased Nrf2 expression, as compared to older animals (noted by
Sachdeva et al. [68]). Elevated cysteine is also known to be detrimental, as it may lead to
glutamate-induced excitotoxicity [69, 70]. Although the cysteine level was significantly
lower in the NACA+NaIO3 group, it was still higher than in the control group.
Our results also showed that NACA decreased NaIO3-induced lipid peroxidation
in the ONL, which was measured by 4-hydroxynonenal (4-HNE) formation. Free radical
chain reactions, initiated by oxygen or light, can damage molecules in the photoreceptor
outer segments containing large concentrations of long-chain PUFAs that are particularly
susceptible to lipid peroxidation and form toxic by-products such as malondialdehyde
(MDA) and 4-HNE, which have been measured in the ONL in other studies [71]. Lipid
peroxidation by-products can induce further production of ROS [72], which overwhelms
repair mechanisms and ultimately leads to photoreceptor death and impaired visual
potential. This is consistent with our ERG results and ONL thickness measurements.
To gain further insight into the mechanism of retinal degeneration induced by
NaIO3, we quantified the levels of phosphatase and tensin homolog deleted on
chromosome 10 (PTEN) and phosphorylated PTEN (p-PTEN), using Western blot. PTEN
can be inactivated by either phosphorylation or thiol oxidation [73, 74], and it has been
shown that phosphorylation of PTEN at specific residues, namely Ser380, Thr382, or
Thr383, decreases its association with junctional proteins [35]. Our results showed both
PTEN and p-PTEN levels were increased in the NaIO3 group. PTEN lipid phosphatase
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activity can alter and inhibit PI3K/AKT/mTOR signalling (a known cell proliferation and
survival pathway) [38, 75, 76]. However, when PTEN was inactivated, the resulting
upregulation of mTORC1 through increased PI3K/Akt signaling can prolonged cone
photoreceptor survival even during RPE cell malfunction or death in the NaIO3 model
[77]

. Similar to its effect on GSH levels, NaIO3-induced PTEN elevation may be the result

of an active cellular defense against oxidative stress. Inactivation of PTEN leads to an
epithelial-to-mesenchymal transition of RPE cells resulting in their migration out of the
retina. Other independent studies, however, indicate that PTEN can be phosphorylated by
ROS-activated PI3K [78]. Although ROS inactivation of PTEN is usually transient,
compromised antioxidant defenses in aged RPE cells might fail to protect PTEN, leading
to longer-term inactivation [77].
In summary, NACA eye drops exhibit some protective effects against NaIO3induced neuroretinal damage in a mouse model of AMD. NaIO3-induced oxidative stress
was evidenced by higher levels of lipid peroxidation by-product 4-HNE that was
measured in the retina of animals receiving NaIO3 injections. Even so, elevated cysteine
and GSH in these animals may be indicative of upregulated antioxidant defense
mechanisms. PTEN and its inactive form, p-PTEN, play an important role in cell
adhesion and PI3K/AKT/mTOR signaling. While both forms were found to be increased
in the retina after NaIO3 injection, the rise in PTEN levels was proportionally greater than
that of p-PTEN, likely downregulating survival signaling and resulting in photoreceptor
death and ONL thinning. In NACA-treated animals, the effect on the ratio of PTEN to pPTEN was even more pronounced. At the cellular level, NACA eye drops prevented
ONL thinning but did not entirely protect RPE integrity, which may explain the
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diminished a- and b-wave waveforms observed in the ERG of these animals. Overall,
NACA eye drops maintained partially visual function for a short time after administration
of a high dose of NaIO3 (75 mg/kg), but NACA was unable to halt progression of
neuroretinal damage for the duration of the experiment.

5. CONCLUSIONS

The primary objective of this study was to examine the effects of NACA eye
drops on the preservation of neuroretina in a chemically-induced macular degeneration
model. The eye drops could possibly be more conveniently administered in real-life
cases. Our results showed that NACA eye drops provided short-term photoreceptor
protection following NaIO3-induced damage. The increased GSH and cysteine levels in
the NaIO3-treated groups may indicate that antioxidant defense mechanisms in the
affected cells had been mobilized against the effects of the toxic lipid peroxidation byproduct (4-HNE) in the ONL, and NACA eye drops were able to reduce the 4-HNE
accumulation. In real life, dry AMD is a slowly progressing disease, and once it has been
discovered, an effective eye drop formulation may stop the progression of dry AMD to
the more severe wet AMD. Currently, there are no available experimental animal models
that perfectly replicate all pathological features of dry AMD. This experimental model of
acute retinal degeneration more closely approximates advanced stages of the disease but
is not necessarily representative of AMD pathology in the majority of patients. However,
these results can provide valuable support for further investigation of NACA eye drops as
a potential therapeutic agent in age-related eye disease.
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SECTION

4. PRELIMINARY DATA FOR IN VITRO MODEL

Before investigating chemically induced retinal degeneration in in vivo, we supplemented
our research by applying the same method in vitro with HRPEpiC, a primary culture of
human retinal pigment epithelial cells. The purpose of this study was to evaluate redox
status following NaIO3-induced oxidative stress and the protective effects of NACA.
4.1. RESULTS
4.1.1. Protection by NACA Against Sodium Iodate-Induced Cell Death. The
cytotoxic effects of NaIO3 were evaluated in HRPEpiC after 24 hours of treatment. NaIO3
induced cytotoxicity in a dose-dependent manner (Figure 4.1), and pre-incubation with
0.5 mM NACA for 4 hours prior to NaIO3 treatment increased cell viability. Results are
reported as percentage of the control. The cell viability was 65.5 ± 4.1% in the 5 mM
NaIO3 group and 104.5 ±7.7 % in the NACA-pretreated NaIO3 group (n = 3-5).
4.1.2. The Protective Effect of NACA Against NaIO3-Induced ROS
Formation in HRPEpi Cells. We further investigated the protective effect of NACA
against NaIO3-induced oxidative damage by determining levels of ROS formation in
HRPEpiC (Figure 4.2). Fluorescence measured in the cells was indicative of intracellular
ROS. The ROS levels in the 5 mM and 15 mM NaIO3 groups were 3.96 ± 0.13 and 4.61
± 0.15 times that of the control group, respectively (P < 0.001). The ROS level was 3.33
± 0.40 times that of the control in the NACA + 5 mM NaIO3 group (P < 0.05) and 3.61 ±
0.61 times the control level in the NACA + 15 mM NaIO3 group (P < 0.001).
pretreatment with NACA for 4 hours diminished NaIO3-induced ROS generation.
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Figure 4.1 Comparison of NaIO3 cytotoxicity with and without NACA in HRPEpiC.
Cells were pretreated with either 0.5 mM NACA or control media for 4 hours. This was
replaced by media with various concentrations of NaIO3 in which the cells were cultured
for another 24 hours.
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Figure 4.2 ROS levels in HRPEpiC after 4 hours of pretreatment with NACA and another
3 hours of treatment with increasing concentration of NaIO3.
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4.1.3. Intracellular Glutathione Levels. To investigate the intracellular thiol
antioxidant levels as a consequence of NaIO3-induced ROS generation, GSH levels were
measured at two different time points during the course of the experiment. Figure 4.3A
shows the GSH levels after 3 hours of NaIO3 treatment, and Figure 4.3B shows the GSH
levels after 24 hours of NaIO3 dosing. After 24 hours, the GSH levels were significantly
increased in the 5 mM NaIO3 group (99.4 ± 9.1 nmol/mg protein, P < 0.001), but they
were close to the control level in the 15 mM NaIO3 group. In the 20 mM NaIO3 group,
the GSH levels were significantly decreased compared to the control group (14.1 ± 6.6
nmol/mg protein, P < 0.001). The GSH levels in NACA + 5 mM NaIO3, NACA + 15
mM NaIO3, and NACA + 20 mM NaIO3 groups were 88.9 ± 7.1, 26.6 ± 3.3 and 4.4 ± 3.5
nmol/mg protein, respectively. The cysteine levels in the control, 0.5 mM NACA, 5 mM
NaIO3, and NACA+NaIO3 groups were 0.53 ± 0.24, 1.85 ± 0.48, 1.11 ± 0.09 and 0.65 ±
0.25 nmol/mg protein, respectively (n = 8 in control and 0.5 mM NaIO3 groups; n = 4 in
other groups).
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Figure 4.3 Intracellular GSH levels in HRPEpiC.
(A) GSH levels were measured after 3 hours of NaIO3 treatment. (B) GSH levels were
measured after 24 hours of NaIO3 treatment with and without NACA pretreatment.
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4.1.4. Glutathione Reductase Activity. Glutathione reductase (GR) reduces
GSSG to generate GSH and is a very important enzyme for glutathione homeostasis. The
GR levels in the control, 0.5 mM NACA, 5 mM NaIO3, and NACA+NaIO3 groups were
25.1 ± 1.5, 23.5 ± 0.7, 20.8 ± 0.9 and 21.7 ± 0.5 mU/mg protein, respectively (Figure
5.4).
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Figure 4.4 Glutathione reductase (GR) levels.
NaIO3 reduced GR activity after 24-hour dosing, and pretreatment with 0.5 mM NACA
did not improve GR activity.
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5. PRELIMINARY DATA FOR IN VIVO MODEL

The rd10+/+ strain is a spontaneous missense point mutation in Pde6 (cGMP
phosphodiesterase 6B in rod receptors) that results in increased levels of cGMP and leads
to elevated ROS and oxidative stress. To further assess the effectiveness of NACA eye
drops, we utilized 1-week old rd10+/+ mice with C57BL/6 mice as controls. The
experimental design is outlined in Figure 5.1.
Because retinal degeneration begins before the rd10+/+ mice open their eyes on
postnatal day (P) 17, it was necessary to change our initial research design and administer
NACA via intraperitoneal (IP) injection to study its preventative effects. From P8, IP
injections of either sodium phosphate buffer or 250 mg/kg NACA were administered
once daily until P16. Eye drops (1% NACA/vehicle, 3 times daily, 4 drops per time) were
started on P17 and continued until P25. The mice were sacrificed on P26, and the eyes
were removed immediately after sacrifice. Retinal sections were evaluated by a masked
observer.

Figure 5.1 Experimental design for rd10+/+ model.
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Our results showed that ONL thinning in rd10+/+ mice had been significantly
prevented with NACA eye drops when compared to retinal sections from mice given
buffer eye drops. Figure 5.2A shows representative images of H&E staining for retinal
sections and ONL thickness in the experimental groups.
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Figure 5.2 NACA eye drops prevented the reduction of ONL thickness in rd10+/+.
(A)Representative images of H&E staining for retinal sections and (B) the average ONL
thickness for each treatment group ( *P < 0.05 & *** P < 0.001 compared to the control
group).
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6. CONCLUSION

AMD is a leading cause of irreversible blindness in the Western world. Oxidative
stress plays a significant role in the progression of AMD, and the clinically available
treatments are limited. With the prevalence of AMD and other retinal degenerative
disorders expected to double in the coming decades, the development of more effective
therapies to prevent their progression is imperative. Because these conditions are closely
linked to oxidative stress, we designed an in vitro and an in vivo model to investigate the
effectiveness of the thiol antioxidant NACA in preventing retinal pigment epithelial cell
and retinal cell damage.
In the TBHP-induced HRPEpiC model, our data indicates that TBHP generated
ROS, which reduced cell viability, depleted GSH levels, and inhibited GR activity. The
treatment of retinal pigment epithelium with NACA protected against TBHP-induced
cellular injury. NACA also inhibited oxidative stress-related breakdown of the bloodretinal barrier as measured by TEER. The proposed mechanism of action involves NACA
scavenging existing reactive oxygen species and increasing levels of reduced glutathione.
Our results indicate that NACA has the potential to become an effective therapeutic agent
by enhancing antioxidant defenses while removing pathologically relevant ROS.
In the NaIO3-induced retinal degeneration model, NaIO3 increased ROS
generation, leading to oxidative stress and cell death. NACA pretreatment helped protect
HRPEpiC against NaIO3-induced ROS formation, although it was not sufficient to restore
GSH levels after depletion by NaIO3. Furthermore, we investigated the beneficial effects
of NACA eye drops in a chemically induced retinal degeneration model. Our results
showed that NACA eye drops improved photoreceptor function following NaIO3-induced
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oxidative stress. NACA eye drops also reduced accumulation of the toxic lipid
peroxidation by-product 4-HNE in the retina. These results support further investigation
of NACA eye drops as a potential therapeutic agent in age-related eye disease.
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